📖 Core Concepts
Core Concepts: Biochemistry II: Metabolism, Regulation, and Bioenergetics
Primary references: [Nelson & Cox, 2021] (Lehninger, 8th ed.) and [Berg et al., 2019] (Stryer, 9th ed.). Key paper for the ATP synthase unit: [Boyer, 1997], Annual Review of Biochemistry 66:717–749, DOI 10.1146/annurev.biochem.66.1.717.
A note on that citation. The course list gives this paper the title "The Rotary Mechanism of ATP Synthase" and no author. The article at that DOI is Paul D. Boyer's review, published as "The ATP synthase—a splendid molecular machine." It is the right paper for this topic. I cite it below as [Boyer, 1997], under its published title.
0. What Is This Subject Really About?
CHEM401 asked how a protein's structure explains what it does. This course asks how thousands of those proteins, all working at once inside one cell, add up to a living system. It is the difference between knowing how a transistor works and knowing how a computer runs.
Metabolism is often taught as a wall of pathways to memorize. Resist that. Underneath the charts, metabolism answers three engineering problems:
- The energy problem. Life needs a steady supply of free energy to stay far from equilibrium, but its food arrives in lumps (a meal, a burst of sunlight). Metabolism converts irregular fuel into a few standardized energy carriers: ATP, GTP, NADH, NADPH, and a membrane proton gradient. These carriers can be spent anywhere in the cell.
- The materials problem. The same small molecules (acetyl-CoA, pyruvate, oxaloacetate, ribose-5-phosphate, α-ketoglutarate) are both fuel to burn and building blocks for new molecules. The cell has to decide, moment to moment, which use wins.
- The control problem. Opposing pathways, such as glycolysis and gluconeogenesis or fatty acid synthesis and oxidation, often run in the same compartment. If both ran at full speed together, the cell would burn ATP in a pointless loop. Regulation lets one pathway run while its opposite is shut off, and it coordinates this across organs through hormones.
The chemistry itself is familiar. From CHEM201/202 you know aldol additions, Claisen condensations, Schiff base formation, hydride transfers, decarboxylations of β-keto acids, and nucleophilic acyl substitution. Metabolism uses only a handful of reaction types, over and over, in different contexts. [Nelson & Cox, 2021] list roughly six classes:
- C–C bond formation and cleavage (aldol, Claisen);
- internal rearrangements, isomerizations, and eliminations;
- free-radical reactions;
- group transfers (especially phosphoryl and acyl);
- oxidation–reductions.
Once you see the repeating moves, the pathways become readable.
A good mental image: metabolism is a city's economy. ATP is cash. NADH and NADPH are two separate bank accounts, one for paying off debts (catabolism) and one for building projects (anabolism). The proton gradient is the power grid. Hormones are central bank policy. Allosteric effectors are local shopkeepers reacting to what's on their shelves.
1. Bioenergetics Revisited: Free Energy, Phosphoryl Transfer, and Coupling
1.1 The governing equation
Everything starts from the relationship you derived in CHEM301:
ΔG = ΔG°′ + RT ln Q ΔG°′ : standard transformed free energy (pH 7, 1 M reactants, [H₂O] folded in) Q : mass-action ratio [products]/[reactants] under actual cellular conditions RT ≈ 2.58 kJ/mol at 37 °C
The key lesson: ΔG°′ tells you about a reaction under conditions that never occur in a cell. ΔG tells you what actually happens. Most metabolic reasoning, especially about regulation, depends on the actual ΔG.
1.2 Why ATP? Phosphoryl group transfer potential
Hydrolysis of ATP to ADP + Pi has ΔG°′ ≈ −30.5 kJ/mol [Nelson & Cox, 2021]. Under real cellular conditions ([ATP] in the mM range, [ADP] and [Pi] much lower), the actual value is more like −50 to −65 kJ/mol. The cell keeps ATP far from hydrolysis equilibrium, and that displacement is what stores the energy.
The large negative ΔG°′ has several sources:
- Electrostatic repulsion relief. The four negative charges on ATP are crowded together, and hydrolysis separates them.
- Resonance stabilization of Pi. Free orthophosphate has more resonance forms than the bound phosphoryl group.
- Ionization. ADP releases a proton at pH 7, which is entropically favorable.
- Greater solvation of the products.
The real conceptual point is that ATP sits in the middle of the phosphoryl transfer scale:
Compound ΔG°′ of hydrolysis (kJ/mol)
-----------------------------------------------------
Phosphoenolpyruvate (PEP) −61.9
1,3-Bisphosphoglycerate −49.3
Phosphocreatine −43.0
ATP → ADP + Pi −30.5
Glucose 1-phosphate −20.9
Glucose 6-phosphate −13.8
Glycerol 3-phosphate −9.2
(values from Nelson & Cox, 2021)
Because ATP is intermediate, it can receive phosphoryl groups from higher-potential donors (PEP, 1,3-BPG) and donate them to lower-potential acceptors (glucose, glycerol). It works as a universal adapter, much like a common currency between many smaller ones.
Why is PEP so high? When the phosphoryl group leaves, the product is enolpyruvate. Enolpyruvate then tautomerizes to the much more stable keto form of pyruvate. Most of PEP's large ΔG°′ comes from this tautomerization, not from the P–O bond itself. In effect, PEP is a "spring-loaded" enol held in place by a phosphate. This is one of the most elegant features of glycolysis.
1.3 Coupling: how unfavorable reactions are made to happen
A recurring misreading is that ATP hydrolysis "releases energy that drives" a reaction, as if heat were passed along. That never happens. Coupling works through shared intermediates. For glutamine synthesis:
Uncoupled: Glu + NH₄⁺ → Gln + H₂O ΔG°′ = +14.2 kJ/mol Coupled (two steps, same active site): (1) Glu + ATP → γ-glutamyl phosphate + ADP (acyl phosphate intermediate) (2) γ-glutamyl phosphate + NH₄⁺ → Gln + Pi Net: Glu + NH₄⁺ + ATP → Gln + ADP + Pi ΔG°′ = +14.2 − 30.5 = −16.3 kJ/mol
ATP's job is to convert a poor leaving group (–OH, released as water) into an excellent one (phosphate). This is the same strategy you used in CHEM202 when you activated a carboxylic acid with SOCl₂ or a carbodiimide. Biology simply uses ATP as its activating reagent.
A related trick: some reactions split ATP into AMP + PPi, and inorganic pyrophosphatase then hydrolyzes the PPi to 2 Pi. Removing a product drives the reaction strongly forward (Le Chatelier). This makes the reaction effectively irreversible and costs two phosphoanhydride bonds. Examples include fatty acyl-CoA synthetase, aminoacyl-tRNA synthetases, and UDP-glucose formation.
1.4 Reducing equivalents: electrons as currency
Redox energy follows the electrochemistry from CHEM102:
ΔG°′ = −n F ΔE°′ For NADH → O₂: NAD⁺/NADH E°′ = −0.320 V ½O₂/H₂O E°′ = +0.816 V ΔE°′ = 1.136 V; n = 2 ΔG°′ = −(2)(96.5 kJ V⁻¹ mol⁻¹)(1.136 V) ≈ −220 kJ/mol
That is the energy of several ATP molecules, carried by one hydride ion. Mitochondria break it into small steps so the energy can be captured rather than lost as heat.
NAD⁺ and NADP⁺ differ only by one phosphate on the 2′-hydroxyl of adenosine, yet the cell keeps them in very different redox states:
- NAD⁺/NADH is kept oxidized. The free cytosolic ratio is roughly several hundred to one. This favors oxidation of fuels, which is what catabolism needs.
- NADP⁺/NADPH is kept reduced. The ratio is on the order of 0.01. This favors reduction in biosynthesis and antioxidant defense.
This is the "two bank accounts" idea made physical. The same nicotinamide chemistry runs in opposite directions in the same cell, at the same time, because enzymes can tell the two pools apart by one phosphate group.
1.5 Energy charge and the adenylate kinase amplifier
Atkinson summarized the cell's ATP status with the adenylate energy charge [Atkinson, 1968]:
Energy charge = ([ATP] + ½[ADP]) / ([ATP] + [ADP] + [AMP]) (normally ≈ 0.85–0.95)
A more subtle point comes from adenylate kinase, which keeps this reaction near equilibrium:
2 ADP ⇌ ATP + AMP K ≈ 1
Because [ATP] is much larger than [AMP], a small fractional drop in ATP produces a large fractional rise in AMP. A 10% fall in ATP can raise AMP several-fold. AMP is therefore a much more sensitive alarm signal than ATP itself.
This is why PFK-1, glycogen phosphorylase b, fructose-1,6-bisphosphatase, and AMPK all respond to AMP. The cell is reading an amplified signal. If you know op-amps from PHYS202, the analogy fits well: adenylate kinase is the amplifier.
2. The Logic of Pathways: Equilibrium, Irreversibility, and Control Points
Here is the single most useful organizing principle for this course. Look at the actual ΔG values for glycolysis in erythrocytes [Nelson & Cox, 2021]:
- Seven of the ten reactions have ΔG close to zero. They operate near equilibrium and can run in either direction depending on substrate and product levels.
- Three reactions are far from equilibrium and strongly negative:
- hexokinase, ≈ −33 kJ/mol;
- PFK-1, ≈ −22 kJ/mol;
- pyruvate kinase, ≈ −17 kJ/mol.
Several consequences follow:
- The far-from-equilibrium steps are where regulation lives. A near-equilibrium enzyme is usually present in excess, and its net flux is set by mass action. Inhibiting it partway barely changes flux. A far-from-equilibrium enzyme is kinetically limiting, so changing its activity changes pathway flux.
- The near-equilibrium enzymes can be shared by opposing pathways. Gluconeogenesis reuses the seven reversible glycolytic enzymes and needs dedicated "bypass" enzymes only at the three irreversible steps.
- Opposing pathways must differ in at least one step, and that step must be separately regulated. If glycolysis and gluconeogenesis were exact reverses, thermodynamics would force them to run at the same net rate. No independent control would be possible.
2.1 Substrate cycles: wasteful or clever?
If PFK-1 (F6P → F1,6BP, consuming ATP) and FBPase-1 (F1,6BP → F6P + Pi) both run at once, the net result is ATP hydrolysis and nothing else. This is called a "futile cycle."
It is not necessarily futile. A small, regulated amount of cycling makes the net flux far more sensitive to effectors. Suppose forward flux is 100 and reverse is 90, so net flux is 10. A 10% increase in forward flux and a 10% decrease in reverse flux shifts the net from 10 to 29, nearly a threefold change. Some insects use deliberate cycling to generate heat, warming flight muscles before takeoff. Treat substrate cycles as a cost the cell pays for sensitivity.
2.2 Control is distributed (a gentle corrective)
Textbooks name "rate-limiting steps." Metabolic control analysis [Kacser & Burns, 1973] showed that control over flux is usually shared among several enzymes. Each enzyme has a flux control coefficient:
C_J^E = (∂J/J) / (∂E/E) Summation theorem: Σᵢ C_J^Eᵢ = 1
Overexpressing PFK-1 alone in yeast barely increases glycolytic flux. Control shifts elsewhere: to transport, to ATP demand, or to downstream steps. This connects directly to the linear algebra in MATH301, since the stoichiometric matrix and its null space underlie flux balance analysis. Use "rate-limiting step" as a teaching shorthand, but know it is an approximation.
3. Glycolysis: The Ancient Core
Glycolysis converts one glucose (C₆) to two pyruvate (C₃) and yields a net 2 ATP and 2 NADH. It is probably the oldest energy-harvesting pathway, and it is nearly universal. It needs no oxygen, which fits a planet that had little O₂ for its first two billion years.
3.1 The ten enzymes, organized by chemical logic
Preparatory phase (spend 2 ATP):
- Hexokinase. Glucose + ATP → glucose-6-phosphate (G6P). This traps glucose in the cell, because the charged G6P cannot leave through GLUT transporters. It is the classic example of induced fit: the two lobes close around glucose, which shields ATP from water. Without that closure, the enzyme would simply hydrolyze ATP.
- Phosphohexose isomerase. G6P ⇌ fructose-6-phosphate. The ring opens, an enediol intermediate forms, and the aldose becomes a ketose. Why bother? It moves the carbonyl to C2, so the later aldol cleavage gives two C₃ fragments instead of a C₂ and a C₄.
- Phosphofructokinase-1 (PFK-1). F6P + ATP → fructose-1,6-bisphosphate. This is the committed step and the main control point.
- Aldolase. F1,6BP ⇌ dihydroxyacetone phosphate (DHAP) + glyceraldehyde-3-phosphate (G3P). It is a retro-aldol reaction. Vertebrate (class I) aldolase forms a Schiff base between the substrate's C2 carbonyl and an active-site Lys. The protonated iminium acts as an electron sink, just like the enamine and iminium chemistry from CHEM202. Even with ΔG°′ ≈ +23.8 kJ/mol, the reaction proceeds because [F1,6BP] is low and the products are removed.
- Triose phosphate isomerase (TPI). DHAP ⇌ G3P via an enediol intermediate. TPI approaches the diffusion limit (kcat/KM ≈ 10⁸–10⁹ M⁻¹s⁻¹). It is often called a "perfect" enzyme, and its catalysis is limited by how fast substrate can reach it, not by chemistry.
Payoff phase (gain 4 ATP and 2 NADH per glucose):
- Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). G3P + NAD⁺ + Pi → 1,3-BPG + NADH. Learn this mechanism thoroughly; see 3.2.
- Phosphoglycerate kinase. 1,3-BPG + ADP → 3-phosphoglycerate + ATP. This is the first substrate-level phosphorylation, meaning a high-energy acyl phosphate passes its phosphoryl group directly to ADP.
- Phosphoglycerate mutase. 3-PG ⇌ 2-PG through a 2,3-bisphosphoglycerate intermediate and a phospho-His on the enzyme.
- Enolase. 2-PG ⇌ PEP + H₂O. Dehydration barely changes the total free energy, but it redistributes it, creating the high-potential enol phosphate. Fluoride inhibits enolase (as a Mg²⁺–F⁻–phosphate complex), which is relevant to blood-sampling tubes.
- Pyruvate kinase. PEP + ADP → pyruvate + ATP. This is the second substrate-level phosphorylation, driven by enol-to-keto tautomerization.
3.2 The GAPDH mechanism: how oxidation energy becomes phosphoryl energy
This is perhaps the most instructive single mechanism in glycolysis, because it shows how oxidation energy is captured in a bond:
(a) Cys149–SH attacks the aldehyde C1 of G3P → thiohemiacetal (b) Hydride transfer from C1 to enzyme-bound NAD⁺ → thioester (enzyme–S–C(=O)–R) + NADH (c) NADH leaves; fresh NAD⁺ binds (d) Pi attacks the thioester carbonyl (phosphorolysis) → 1,3-BPG (acyl phosphate) + free Cys–SH
Aldehyde oxidation to a carboxylic acid is very favorable (≈ −43 kJ/mol). If the aldehyde were simply oxidized to a free carboxylate, that energy would be lost as heat. Instead, the energy is held in a thioester and then transferred into an acyl phosphate, so oxidation is coupled to phosphorylation.
Arsenate experiment. Arsenate (AsO₄³⁻) can replace Pi in step (d), forming 1-arseno-3-phosphoglycerate. That compound hydrolyzes on its own, so glycolysis continues but the ATP from step 7 is lost. This explains part of arsenate's toxicity, and it neatly demonstrates the coupling.
3.3 Regulation
Hexokinase isozymes. Hexokinases I–III (muscle and most tissues) have KM ≈ 0.1 mM for glucose and are inhibited by their product, G6P. Hexokinase IV, called glucokinase (liver and pancreatic β-cells), behaves differently:
- its S0.5 is about 10 mM, near or above fasting blood glucose;
- it shows sigmoidal kinetics;
- it is not inhibited by G6P;
- it is controlled by glucokinase regulatory protein, which holds it in the nucleus.
The result: muscle grabs glucose whenever it is available, while liver takes it up only when glucose is plentiful. Glucokinase is a glucose sensor as well as an enzyme.
PFK-1 is the main control point:
- Inhibited by ATP, acting at an allosteric site separate from the substrate site. ATP is both a substrate and an inhibitor.
- Inhibited by citrate, which signals that the TCA cycle is backed up.
- Activated by AMP and ADP, the amplified low-energy signal.
- Activated most powerfully by fructose-2,6-bisphosphate (F2,6BP).
The F2,6BP system. F2,6BP is not a glycolytic intermediate. It is a dedicated signaling molecule made and destroyed by one bifunctional enzyme, PFK-2/FBPase-2:
Glucagon → cAMP → PKA → phosphorylates PFK-2/FBPase-2 (liver isoform)
→ kinase domain OFF, phosphatase domain ON
→ [F2,6BP] falls
→ PFK-1 less active, FBPase-1 less inhibited
→ net: gluconeogenesis ↑, glycolysis ↓
Insulin → phosphoprotein phosphatase → dephosphorylates PFK-2/FBPase-2
→ [F2,6BP] rises → glycolysis ↑, gluconeogenesis ↓
F2,6BP activates PFK-1 and inhibits FBPase-1, so one small molecule sets the direction at the F6P ↔ F1,6BP step. This is reciprocal regulation at its clearest.
Pyruvate kinase:
- Activated by F1,6BP (feed-forward activation: when an upstream step speeds up, it prepares the downstream exit).
- Inhibited by ATP, alanine, and acetyl-CoA.
- The liver (L) isozyme is inactivated by PKA phosphorylation. In the fasted liver, this keeps PEP made by gluconeogenesis from being converted straight back to pyruvate.
3.4 What happens to pyruvate and NADH
Glycolysis needs NAD⁺ to continue. The fate of pyruvate is really a decision about how to regenerate it:
- Aerobic: pyruvate enters mitochondria and is oxidized fully. NADH is reoxidized by the electron transport chain, reaching it through the malate–aspartate or glycerol-3-phosphate shuttle.
- Anaerobic, in animals: lactate dehydrogenase reduces pyruvate to lactate and regenerates NAD⁺.
- Anaerobic, in yeast: pyruvate decarboxylase (TPP-dependent) and alcohol dehydrogenase produce ethanol and regenerate NAD⁺.
4. Pyruvate Dehydrogenase and the TCA Cycle: The Central Hub
4.1 The pyruvate dehydrogenase complex (PDC)
PDC carries out the oxidative decarboxylation of pyruvate:
Pyruvate + CoA-SH + NAD⁺ → acetyl-CoA + CO₂ + NADH ΔG°′ ≈ −33.4 kJ/mol
This step is irreversible, and that has a major metabolic consequence. Animals cannot convert acetyl-CoA back into pyruvate, so they cannot make net glucose from even-chain fatty acids. Keep this in mind; it explains much of fasting physiology.
The complex has three enzymes and five cofactors:
E1 (pyruvate dehydrogenase; cofactor TPP):
TPP ylide carbanion attacks pyruvate C2 → decarboxylation → hydroxyethyl-TPP
E2 (dihydrolipoyl transacetylase; cofactor lipoamide, plus CoA as substrate):
hydroxyethyl group oxidized onto lipoamide disulfide → acetyl-dihydrolipoamide
acetyl transferred to CoA-SH → acetyl-CoA; lipoamide left fully reduced
E3 (dihydrolipoyl dehydrogenase; cofactors FAD and NAD⁺):
reduced lipoamide → FAD → FADH₂ → NAD⁺ → NADH; lipoamide reoxidized
Thiamine pyrophosphate. The C2 of the thiazolium ring is unusually acidic. Its carbanion (an ylide) acts as an "electron sink" and stabilizes the carbanion that forms when pyruvate loses CO₂. This is the biological version of umpolung (polarity reversal), comparable to cyanide or N-heterocyclic carbene catalysis of the benzoin condensation. Thiamine deficiency (beriberi, Wernicke–Korsakoff syndrome) hits the brain hard because neurons rely heavily on glucose oxidation.
The lipoyl "swinging arm." Lipoic acid is attached by an amide bond to the ε-amino group of a Lys on E2. The combined lysyl-lipoyl tether is about 14 Å long and moves the substrate among the three active sites, a form of substrate channeling. Intermediates never leave the complex, which keeps local concentrations high and protects reactive species. You will see the same design in the phosphopantetheine arm of fatty acid synthase (Section 8).
E3 is shared among PDC, α-ketoglutarate dehydrogenase, and branched-chain α-keto acid dehydrogenase. These three complexes are evolutionary relatives, and remembering that helps you predict their behavior.
Regulation of PDC:
- Product inhibition: acetyl-CoA inhibits E2, and NADH inhibits E3.
- Covalent modification. PDH kinase phosphorylates specific Ser residues on E1 and inactivates it.
- The kinase is activated by ATP, NADH, and acetyl-CoA, the signals that the cell has enough energy.
- The kinase is inhibited by pyruvate and ADP, the signals that more oxidation is needed.
- Reactivation. PDH phosphatase dephosphorylates and reactivates E1. It is stimulated by Ca²⁺ (muscle contraction) and indirectly by insulin in adipose tissue.
4.2 The TCA cycle: eight enzymes, one catalytic loop
1. Citrate synthase: acetyl-CoA + OAA + H₂O → citrate + CoA (Claisen-like; ΔG°′ ≈ −32 kJ/mol) 2. Aconitase: citrate ⇌ isocitrate (via cis-aconitate; [4Fe-4S] cluster) 3. Isocitrate dehydrogenase: isocitrate + NAD⁺ → α-KG + CO₂ + NADH 4. α-KG dehydrogenase cplx: α-KG + CoA + NAD⁺ → succinyl-CoA + CO₂ + NADH 5. Succinyl-CoA synthetase: succinyl-CoA + GDP (or ADP) + Pi → succinate + GTP (or ATP) + CoA 6. Succinate dehydrogenase: succinate + FAD(enzyme-bound) → fumarate + FADH₂ → electrons to ubiquinone 7. Fumarase: fumarate + H₂O ⇌ L-malate (stereospecific trans addition) 8. Malate dehydrogenase: L-malate + NAD⁺ ⇌ OAA + NADH (ΔG°′ ≈ +29.7 kJ/mol) Net per acetyl-CoA: 3 NADH + 1 QH₂ (via FADH₂) + 1 GTP/ATP + 2 CO₂
Mechanisms to know:
- Citrate synthase. Acetyl-CoA forms an enol(ate) that attacks the OAA carbonyl, giving a citroyl-CoA intermediate. Hydrolysis of this thioester then pulls the reaction forward. The large negative ΔG°′ is needed because malate dehydrogenase (step 8) is very unfavorable. The cycle keeps [OAA] extremely low, and citrate synthase drains it efficiently.
- Isocitrate dehydrogenase. First, the secondary alcohol is oxidized by hydride transfer to NAD⁺, giving enzyme-bound oxalosuccinate. Oxalosuccinate is a β-keto acid, so it decarboxylates easily (Mn²⁺ or Mg²⁺ stabilizes the enolate) to give α-KG. This is a CHEM202 pattern: oxidize to create a β-keto acid, and decarboxylation follows naturally. The NAD⁺-dependent mitochondrial isoform is allosterically activated by ADP and Ca²⁺ and inhibited by ATP and NADH.
- α-Ketoglutarate dehydrogenase. It uses the same chemistry as PDC (TPP, lipoamide, CoA, FAD, NAD⁺), applied to a different α-keto acid. The product, succinyl-CoA, holds part of the decarboxylation energy as a thioester, and step 5 later recovers that energy as GTP.
- Succinate dehydrogenase. It is the only TCA enzyme embedded in the inner mitochondrial membrane, and it is also Complex II of the electron transport chain. It oxidizes a C–C single bond to a trans double bond. That oxidation is not exergonic enough to reduce NAD⁺ (succinate/fumarate E°′ ≈ +0.03 V), so FAD, covalently attached to a His, accepts the electrons and passes them through Fe–S clusters to ubiquinone. Malonate, a close structural analog, is the classic competitive inhibitor.
4.3 Surprising things about the TCA cycle
- The cycle uses no O₂ directly. It still stops at once without oxygen, because NAD⁺ and FAD are regenerated only through the electron transport chain.
- The two CO₂ released in one turn do not come from the acetyl group that just entered. They come from carbons that were already part of OAA. Isotope tracing makes this clear.
- Citrate is symmetric, yet aconitase treats its two –CH₂COO⁻ arms differently. Ogston's "three-point attachment" explanation shows that an achiral molecule can react stereospecifically at a chiral active site. Citrate is prochiral.
- The cycle is catalytic. One OAA can process unlimited acetyl-CoA. The same property means that pulling intermediates out for biosynthesis drains the cycle.
4.4 Amphibolic nature and anaplerosis
The TCA cycle is amphibolic, meaning it serves both catabolism and anabolism. Intermediates are constantly withdrawn:
- citrate, exported for fatty acid synthesis;
- α-KG, used for glutamate;
- succinyl-CoA, used for heme;
- OAA, used for aspartate and for gluconeogenesis.
Anaplerotic ("filling up") reactions replace them. The most important in animals is:
Pyruvate + HCO₃⁻ + ATP → oxaloacetate + ADP + Pi (pyruvate carboxylase; biotin; allosterically activated by acetyl-CoA)
The logic is neat. Acetyl-CoA accumulates when there is not enough OAA to combine with it. So acetyl-CoA itself switches on OAA production, and the substrate signals for its own partner.
Biotin (also attached to a Lys) carries activated CO₂ as carboxybiotin. It is another swinging arm. Raw egg white contains avidin, which binds biotin extremely tightly and can cause deficiency.
5. Oxidative Phosphorylation: Chemiosmosis and the Electron Transport Chain
5.1 Mitchell's radical idea
Through the 1950s, biochemists searched without success for a "high-energy intermediate" that would link electron transport to ATP synthesis, as 1,3-BPG does in glycolysis. Peter Mitchell proposed instead that the link is not a molecule at all. It is an electrochemical proton gradient across a membrane [Mitchell, 1961]. The proposal was ignored and ridiculed for years. It won the Nobel Prize in 1978.
The conceptual leap: energy can be stored as a spatial arrangement. Protons moved to one side of an impermeable membrane store energy, much as water held behind a dam does.
The proton-motive force has two components:
Δp = Δψ − (2.303 RT / F) ΔpH (ΔpH = pH_in − pH_out; matrix is more alkaline, so ΔpH > 0)
At 37 °C: 2.303 RT/F ≈ 61.5 mV
Free energy to move 1 mol H⁺ out of the matrix:
ΔG = 2.303 RT ΔpH + F Δψ
(with ΔpH ≈ 0.75 and Δψ ≈ 0.15–0.20 V, magnitude ≈ 19–24 kJ/mol)
[Nelson & Cox, 2021]
In mitochondria, most of Δp is electrical (Δψ), because the inner membrane has very low capacitance per unit area. PHYS202 explains why: Q = CV, and a membrane about 5 nm thick has capacitance near 1 μF/cm². Moving a tiny number of protons, relative to the buffered proton pool, builds a large voltage. The mitochondrial inner membrane is a charged capacitor.
5.2 The four complexes
Complex I NADH:ubiquinone oxidoreductase
FMN → chain of Fe–S clusters → Q. Pumps 4 H⁺ per 2 e⁻.
L-shaped: hydrophilic arm (redox) + membrane arm (proton pumping),
coupled at a distance by conformational change.
Complex II Succinate dehydrogenase
FAD → Fe–S → Q. Pumps 0 H⁺.
Complex III Cytochrome bc₁ complex (ubiquinone:cytochrome c oxidoreductase)
Q cycle. Net 4 H⁺ released to the intermembrane space per 2 e⁻
reaching cytochrome c (2 H⁺ taken up from the matrix).
Cytochrome c Small, soluble, peripheral protein in the intermembrane space; one heme; carries 1 e⁻.
Complex IV Cytochrome c oxidase
Cu_A → heme a → heme a₃/Cu_B binuclear center → O₂.
Per 4 e⁻: 4 "chemical" H⁺ consumed from the matrix to make 2 H₂O, plus 4 H⁺ pumped.
Per 2 e⁻: 2 pumped + 2 consumed.
Totals per 2 e⁻: NADH → O₂: 4 + 4 + 2 = 10 H⁺ translocated
succinate → O₂: 0 + 4 + 2 = 6 H⁺
Ubiquinone (CoQ). CoQ is a lipid-soluble benzoquinone with a long isoprenoid tail (connect to Section 9: it is made from the same isoprenoid building blocks as cholesterol). It diffuses within the membrane and can carry one or two electrons:
Q → semiquinone (Q•⁻) → QH₂
This flexibility lets it connect two-electron donors (NADH, succinate) to one-electron carriers (Fe–S clusters, cytochromes). It acts as an "adapter" between the two-electron and one-electron parts of the chain.
The Q cycle. At the Qo site of Complex III, QH₂ releases 2 H⁺ to the intermembrane space. Its two electrons then split, which is called bifurcation:
- One electron goes through the Rieske Fe–S protein and cytochrome c₁ to cytochrome c.
- The other goes through hemes bL and bH back to a Q at the Qi site on the matrix side.
Two turns are needed to fully reduce one Q at Qi, which takes up 2 matrix H⁺. The net effect is to recycle half the electrons and pump extra protons. It is a clever stoichiometric trick.
Link to CHEM303. Electrons hop between cofactors that are often 10–14 Å apart, through protein, by quantum tunneling. Rates follow Marcus theory and fall off exponentially with distance. The arrangement of cofactors in these complexes is set by tunneling physics.
Why poisons are deadly:
- Complex I is blocked by rotenone.
- Complex III is blocked by antimycin A.
- Complex IV is blocked by cyanide, CO, and azide, which bind heme a₃.
- Uncouplers such as 2,4-dinitrophenol carry H⁺ across the membrane. Electron flow continues, but ATP synthesis stops and the energy is released as heat.
Brown adipose tissue does the uncoupling on purpose with UCP1 (thermogenin). That is how newborns and hibernating animals generate heat without shivering.
5.3 Respiratory control
In intact mitochondria, electron transport is tightly coupled to ATP synthesis. Without ADP, ATP synthase cannot turn, Δp builds to its maximum, and pumping slows until the energy cost of pumping against the gradient matches what electron transfer can supply. Adding ADP restarts respiration.
The result is that ATP demand sets the rate of O₂ consumption, a self-regulating supply chain. Oligomycin, which blocks the Fo proton channel, stops respiration in coupled mitochondria. That observation is direct evidence that electron transport and ATP synthesis are linked through the gradient.
6. ATP Synthase: The Rotary Motor
If one structure in this course deserves careful study, it is this one.
6.1 Architecture
F₁ (matrix side; catalytic; soluble when detached):
α₃β₃ hexamer around a central γ stalk; δ and ε subunits
catalytic sites lie mainly on the β subunits at α/β interfaces
F_o (membrane):
c-ring: 8 c-subunits in bovine mitochondria
(other species ~10–15: about 10 in yeast, 14 in spinach chloroplasts)
a subunit: forms two half-channels for H⁺
b subunits + OSCP: peripheral "stator stalk" that holds α₃β₃ still
Rotor: c-ring + γ + ε (they turn together)
Stator: a + b₂ + δ/OSCP + α₃β₃
6.2 Boyer's binding-change mechanism
Paul Boyer's model came from isotope-exchange experiments, long before any structure existed [Boyer, 1997]. Its central claim is surprising:
The energy of the proton gradient is not used to make the ATP bond. On the enzyme surface, ADP + Pi ⇌ ATP sits near equilibrium. The gradient's energy goes into releasing tightly bound ATP and binding ADP + Pi. This is paraphrased from [Boyer, 1997].
The evidence came from ¹⁸O exchange. Even without a proton gradient, the enzyme rapidly and repeatedly exchanges oxygen between water and the phosphate of bound ATP. This means bound ATP is forming and hydrolyzing back and forth on the enzyme, with an equilibrium constant near 1. The step that needs energy is removing the product.
Each of the three catalytic β subunits cycles through three conformations:
O (open) : low affinity; ATP is released, ADP + Pi enter L (loose) : binds ADP + Pi loosely; catalytically inactive T (tight) : binds ADP + Pi very tightly; ATP forms spontaneously (K ≈ 1 on the enzyme) Each 120° rotation of γ moves every β subunit one step: O → L → T → O At any instant the three β subunits are in three different states. One full 360° turn → 3 ATP.
6.3 How the model was confirmed
- Structure. The 2.8 Å crystal structure of bovine F₁ [Abrahams et al., 1994] showed three β subunits in different conformations at the same moment: one with an ATP analog, one with ADP, and one empty. The asymmetric γ subunit sits in the middle and contacts each β differently, exactly as Boyer predicted. Boyer and John Walker shared the 1997 Nobel Prize in Chemistry (with Jens Skou, for the Na⁺/K⁺-ATPase).
- Watching rotation directly. Noji and colleagues fixed α₃β₃γ upside down on a glass surface, attached a fluorescent actin filament to γ, added ATP, and watched the filament spin under a microscope [Noji et al., 1997]. Running in reverse as an ATPase, F₁ is an ATP-driven rotary motor. Later single-molecule work showed discrete 120° steps.
6.4 From protons to rotation
Each c-subunit has a conserved acidic residue (Asp or Glu) in the middle of the membrane. One full rotation proceeds like this:
- A proton enters from the intermembrane space through a half-channel in subunit a and neutralizes the carboxylate of one c-subunit.
- The neutral residue can now move into the lipid bilayer, so the ring rotates by one step.
- After nearly a full turn, that c-subunit reaches the second half-channel, which opens to the matrix.
- There it releases its proton into the more alkaline matrix.
The Δψ and ΔpH bias the direction, so rotation is driven by a proton "ratchet."
The c-ring size sets the gear ratio:
H⁺ per ATP (synthase alone) = (number of c-subunits) / 3
Bovine (c₈): 8/3 ≈ 2.7 H⁺/ATP
plus ~1 H⁺ for ATP export / ADP + Pi import
(adenine nucleotide translocase + phosphate carrier)
→ ≈ 3.7 H⁺ per ATP delivered to the cytosol
This ATP synthase is a reversible motor powered by protons, built from proteins about 10 nm across. Its efficiency is very high: under physiological conditions the work it does per step closely matches the free energy available. Nothing humans have built at the nanoscale comes close.
6.5 The P/O ratio
P/O (NADH) ≈ 10 H⁺ / 3.7 H⁺ per ATP ≈ 2.7 → textbook value 2.5
P/O (succinate) ≈ 6 H⁺ / 3.7 H⁺ per ATP ≈ 1.6 → textbook value 1.5
ATP per glucose (complete oxidation):
≈ 32 with the malate–aspartate shuttle
≈ 30 with the glycerol-3-phosphate shuttle (cytosolic NADH enters as FADH₂/QH₂)
[Nelson & Cox, 2021; Berg et al., 2019]
The P/O ratio is not an integer. Older textbooks gave 3 and 2, and "38 ATP per glucose." Non-integer ratios make sense once you see that the gradient connects electron flow and ATP synthesis without any fixed molecular stoichiometry. The proton gradient acts like an energy buffer between two separately geared machines.
7. Carbohydrate Storage and Alternatives: Gluconeogenesis, Glycogen, and the Pentose Phosphate Pathway
7.1 Gluconeogenesis: same road, three detours
The brain uses roughly 120 g of glucose per day, and red blood cells depend on it completely, because they have no mitochondria. In fasting, the liver (and to a lesser extent the kidney cortex) makes glucose from non-carbohydrate precursors:
- lactate, recycled from muscle and red cells (the Cori cycle);
- glucogenic amino acids, especially alanine (the glucose–alanine cycle);
- glycerol from triacylglycerol breakdown;
- propionyl-CoA from odd-chain fatty acids.
The three bypasses:
Bypass 1 (pyruvate → PEP), two steps, partly in mitochondria:
pyruvate + HCO₃⁻ + ATP → OAA (pyruvate carboxylase, mitochondrial; needs acetyl-CoA)
OAA + GTP → PEP + CO₂ + GDP (PEPCK; mitochondrial or cytosolic)
OAA cannot cross the inner membrane. It leaves as malate (which also exports reducing
equivalents for the GAPDH reversal) or as aspartate.
Bypass 2: F1,6BP + H₂O → F6P + Pi (fructose-1,6-bisphosphatase-1)
Bypass 3: G6P + H₂O → glucose + Pi (glucose-6-phosphatase; ER lumen; liver/kidney only)
Overall: 2 pyruvate + 4 ATP + 2 GTP + 2 NADH + 4 H₂O → glucose + 4 ADP + 2 GDP + 6 Pi + 2 NAD⁺
(6 phosphoanhydride bonds per glucose)
Glycolysis yields 2 ATP, while gluconeogenesis costs 6. The difference of 4 ATP is the price of making both directions irreversible and independently controllable. Muscle lacks glucose-6-phosphatase, so its glycogen supplies only the muscle itself. The liver is the only major organ that can release free glucose into the blood. (Glucose-6-phosphatase deficiency is von Gierke disease, glycogen storage disease type I.)
Why fat cannot become glucose in animals. Acetyl-CoA entering the TCA cycle adds 2 carbons, and 2 carbons leave as CO₂ in the same turn. No net OAA is produced. Plants and bacteria get around this with the glyoxylate cycle (isocitrate lyase and malate synthase), which skips both decarboxylations. That is how a germinating seed turns stored oil into sugar.
7.2 Glycogen: a branched, rapid-release battery
Glycogen is a highly branched polymer: α-1,4 chains with α-1,6 branches every 8–12 residues, built on the protein primer glycogenin. The branches matter. They create many non-reducing ends where enzymes can work at once, so glucose can be released very quickly. That is essential for a muscle that needs fuel within seconds.
Breakdown. Glycogen phosphorylase carries out phosphorolysis, not hydrolysis:
(glucose)ₙ + Pi → (glucose)ₙ₋₁ + glucose-1-phosphate
- The product is already phosphorylated, which saves the ATP hexokinase would otherwise use. Glycogen-derived glucose therefore gives 3 net ATP in glycolysis instead of 2.
- The enzyme uses PLP, but in an unusual role. Its phosphate group acts as a general acid–base catalyst, not as the familiar Schiff-base electron sink.
- Phosphoglucomutase converts G1P to G6P.
- The debranching enzyme, which has two activities, handles branch points: it moves three glucose residues to another chain, then hydrolyzes the remaining α-1,6-linked glucose to free glucose.
Synthesis:
G1P + UTP → UDP-glucose + PPi (PPi then hydrolyzed: drives the reaction) UDP-glucose + glycogen(n) → glycogen(n+1) + UDP (glycogen synthase; α-1,4)
Branching enzyme then moves a 6–7-residue segment to form an α-1,6 linkage. Note the familiar strategy again: activate the sugar as a nucleotide-sugar, with UDP as a good leaving group.
7.3 The cAMP cascade: amplification by design
Glucagon (liver) or epinephrine (liver, muscle) → GPCR → Gαs·GTP → adenylyl cyclase → cAMP (many per receptor) → PKA (R₂C₂ → 2 active C) → phosphorylase kinase (phosphorylated, activated; also Ca²⁺-activated via its calmodulin δ subunit) → glycogen phosphorylase b → a (Ser14 phosphorylation; activated) → glycogen breakdown Simultaneously, PKA (and other kinases) phosphorylate glycogen synthase a → b (inactivated)
Each step is enzymatic, so the signal is multiplied many times over. A few hormone molecules can mobilize vast amounts of glucose. In addition, the same signal (phosphorylation) turns on degradation and turns off synthesis, which is reciprocal regulation again.
Allosteric controls sit on top of the covalent ones, and they differ by tissue:
- In muscle, phosphorylase b is activated by AMP, so an energy crisis can trigger glycogen breakdown even without hormones.
- In liver, phosphorylase a is inhibited by glucose. Glucose binding exposes Ser14 to phosphatase, and the released PP1 then activates glycogen synthase. The liver enzyme is effectively a blood-glucose sensor.
- Insulin works mainly by activating protein phosphatase 1 and by inhibiting GSK3 (through Akt), so glycogen synthase becomes dephosphorylated and active.
7.4 The pentose phosphate pathway: making NADPH and ribose on demand
Oxidative branch (irreversible; produces NADPH):
G6P + NADP⁺ → 6-phosphoglucono-δ-lactone + NADPH (G6P dehydrogenase; committed step; inhibited by NADPH) lactone + H₂O → 6-phosphogluconate (lactonase) 6-phosphogluconate + NADP⁺ → ribulose-5-P + CO₂ + NADPH (6-phosphogluconate dehydrogenase; oxidative decarboxylation)
Non-oxidative branch (reversible; interconverts sugars):
- Ru5P is isomerized to ribose-5-P or epimerized to xylulose-5-P.
- Transketolase uses TPP to move 2-carbon units, in the same umpolung style as PDC E1.
- Transaldolase uses a Lys Schiff base to move 3-carbon units, like class I aldolase.
These carbon "shuffling" reactions connect pentoses back to glycolytic intermediates such as F6P and G3P.
Because the second branch is reversible, the pathway can run in different modes depending on demand [Berg et al., 2019]:
- Need ribose more than NADPH (for example, a dividing cell making DNA): the non-oxidative branch runs backward from F6P and G3P, without the oxidative steps.
- Need both equally: the oxidative branch alone.
- Need NADPH far more than ribose (for example, adipose tissue making fatty acids): pentoses are recycled to G6P through F6P, and G6P re-enters the oxidative branch. Effectively, glucose is oxidized entirely to CO₂, producing only NADPH.
- Need NADPH and ATP: the pentoses are fed into glycolysis.
Clinical connection to BIOL302. Red blood cells depend on the PPP for NADPH, which keeps glutathione reduced and protects hemoglobin and membranes from oxidative damage. G6PD deficiency causes hemolysis under oxidative stress (fava beans, primaquine). It is common in malarial regions, probably because it offers partial protection against Plasmodium. It is a textbook case of balancing selection.
8. Lipid Metabolism: Mirror-Image Pathways Kept Apart
8.1 Fatty acid oxidation
Fat is the body's densest fuel store: about 37 kJ/g, versus about 17 kJ/g for carbohydrate. It is also stored nearly dry, while glycogen carries about twice its weight in water. A typical adult carries about 1 day of glycogen and roughly a month or more of fat.
Activation and import:
FA + CoA + ATP → fatty acyl-CoA + AMP + PPi (acyl-CoA synthetase, outer mito membrane;
via an acyl-adenylate intermediate; PPi hydrolyzed)
Fatty acyl-CoA + carnitine → fatty acyl-carnitine + CoA (CPT1; outer membrane; INHIBITED by malonyl-CoA)
acyl-carnitine crosses the inner membrane on the translocase
fatty acyl-carnitine + CoA → fatty acyl-CoA + carnitine (CPT2; matrix side)
The carnitine shuttle keeps separate cytosolic and mitochondrial CoA pools. More importantly, it serves as a regulatory gate. Malonyl-CoA, the first committed intermediate of fatty acid synthesis, inhibits CPT1. So whenever the cell is making fat, the fatty acids it makes cannot enter mitochondria to be burned. This prevents a futile cycle with a single metabolite. Of all the regulatory designs in this course, this one is perhaps the most elegant.
The β-oxidation cycle repeats four steps, each removing 2 carbons:
1. Acyl-CoA dehydrogenase (FAD): acyl-CoA → trans-Δ²-enoyl-CoA → electrons to ETF → Q
2. Enoyl-CoA hydratase: → L-3-hydroxyacyl-CoA
3. L-3-hydroxyacyl-CoA DH (NAD⁺): → 3-ketoacyl-CoA + NADH
4. Thiolase (CoA): → acetyl-CoA + acyl-CoA (shortened by 2) [retro-Claisen]
Palmitoyl-CoA (C16) + 7 CoA + 7 FAD + 7 NAD⁺ + 7 H₂O → 8 acetyl-CoA + 7 FADH₂ + 7 NADH + 7 H⁺
ATP yield: 8 acetyl-CoA × 10 = 80; 7 QH₂ × 1.5 = 10.5; 7 NADH × 2.5 = 17.5 → 108
minus 2 (activation: ATP → AMP = 2 phosphoanhydride equivalents) = 106 ATP
Notice that the step sequence matches the TCA cycle's succinate → fumarate → malate → OAA: FAD oxidation of C–C to C=C, hydration, then NAD⁺ oxidation of the alcohol to a ketone. Evolution reused the same chemical logic.
Variations:
- Unsaturated fatty acids need an isomerase, plus a reductase for polyunsaturated ones.
- Odd-chain fatty acids give propionyl-CoA. Propionyl-CoA is carboxylated (biotin) to methylmalonyl-CoA, which methylmalonyl-CoA mutase rearranges to succinyl-CoA. That mutase uses a coenzyme B₁₂ radical mechanism. This route is the small exception that lets a little fat become glucose.
- Very-long-chain fatty acids begin oxidation in peroxisomes, which make H₂O₂ instead of QH₂.
8.2 Ketone bodies: the liver's export fuel
During prolonged fasting, OAA is drawn off for gluconeogenesis. Hepatic acetyl-CoA then cannot enter the TCA cycle fast enough, and the liver converts it to ketone bodies:
2 acetyl-CoA → acetoacetyl-CoA (thiolase) acetoacetyl-CoA + acetyl-CoA → HMG-CoA (mitochondrial HMG-CoA synthase; regulated) HMG-CoA → acetoacetate + acetyl-CoA (HMG-CoA lyase) acetoacetate + NADH ⇌ D-β-hydroxybutyrate + NAD⁺ (or spontaneous decarboxylation → acetone)
The liver makes ketones but cannot use them, because it lacks succinyl-CoA:3-ketoacid CoA transferase (thiophorase). As a result, ketones are an export fuel from liver to heart, muscle, and eventually brain. After several days of starvation, ketones supply a large share of the brain's energy, which spares muscle protein that would otherwise be broken down for gluconeogenesis.
Ketosis is a normal adaptation. Ketoacidosis is the pathology: in uncontrolled type 1 diabetes, the near-absence of insulin lets ketone production run unchecked until the blood's buffering capacity is overwhelmed.
8.3 Fatty acid synthesis: same chemistry, run in reverse
Committed step: acetyl-CoA + HCO₃⁻ + ATP → malonyl-CoA + ADP + Pi (acetyl-CoA carboxylase, ACC; biotin) ACC activated by citrate (polymerization in animals); inhibited by palmitoyl-CoA; inactivated by phosphorylation (AMPK; PKA) FAS cycle (each round adds 2 C; carrier is the ACP phosphopantetheine arm): 1. Condensation (β-ketoacyl-ACP synthase): acyl + malonyl-ACP → β-ketoacyl-ACP + CO₂ + ACP 2. Reduction (NADPH) → D-3-hydroxyacyl-ACP 3. Dehydration → trans-Δ²-enoyl-ACP 4. Reduction (NADPH) → saturated acyl-ACP Palmitate: 8 acetyl-CoA + 7 ATP + 14 NADPH + 14 H⁺ → palmitate + 8 CoA + 7 ADP + 7 Pi + 14 NADP⁺ + 6 H₂O
Why go through malonyl-CoA? A Claisen condensation of two acetyl thioesters is thermodynamically uphill. Adding CO₂ to make malonyl-CoA (spending ATP) and then losing that same CO₂ during the condensation makes the C–C bond formation strongly favorable. The decarboxylation also generates the nucleophilic enolate needed for the reaction.
The CO₂ is a temporary activating group, in, used, and out. Compare the malonic ester synthesis from CHEM202, and note that gluconeogenesis plays the same carboxylate–decarboxylate trick (pyruvate → OAA → PEP).
Synthesis versus oxidation: a mirror held apart.
| Feature | β-Oxidation | Fatty Acid Synthesis |
|---|---|---|
| Location | Mitochondrial matrix | Cytosol |
| Acyl carrier | CoA | Acyl carrier protein (ACP) domain of FAS |
| Redox cofactors | FAD, NAD⁺ (oxidation) | NADPH (reduction) |
| 3-Hydroxyacyl stereochemistry | L | D |
| 2-carbon unit | Released as acetyl-CoA | Donated by malonyl-CoA (C₃) |
| Key regulator | Malonyl-CoA inhibits CPT1 | Citrate activates ACC |
Almost every feature is different, which is what allows both pathways to be controlled independently. The citrate shuttle connects them:
- Acetyl-CoA is made in mitochondria but used for synthesis in the cytosol.
- It leaves the mitochondrion as citrate.
- ATP-citrate lyase splits citrate back to acetyl-CoA and OAA in the cytosol.
- OAA is reduced to malate, and malic enzyme converts malate to pyruvate, producing NADPH.
So the same shuttle delivers both the carbon and part of the reducing power. Exported citrate also activates ACC, which signals "excess fuel, store it."
Mammalian FAS is a single giant multifunctional polypeptide that forms a dimer. All the active sites are linked by the swinging ACP phosphopantetheine arm, a direct structural parallel to the lipoyl arm of PDC.
8.4 Cholesterol and isoprenoids
3 acetyl-CoA → HMG-CoA (cytosolic HMG-CoA synthase) HMG-CoA + 2 NADPH → mevalonate + CoA (HMG-CoA reductase; rate-limiting; statin target; ER membrane) mevalonate → (3 ATP) → isopentenyl pyrophosphate (IPP, C₅) ⇌ dimethylallyl pyrophosphate (DMAPP) C₅ + C₅ → geranyl-PP (C₁₀) → farnesyl-PP (C₁₅) ["head-to-tail" condensations via allylic carbocations] 2 farnesyl-PP → squalene (C₃₀) ["head-to-head"] squalene → 2,3-oxidosqualene → lanosterol (cationic polycyclization: four rings in one step) lanosterol → → cholesterol (C₂₇)
Note the two mitochondrial versus cytosolic HMG-CoA synthases. The same intermediate, HMG-CoA, leads to ketone bodies in the mitochondrion and to cholesterol in the cytosol. Compartment determines its fate.
Beautiful chemistry. The squalene-to-lanosterol cyclization forms four rings and seven stereocenters in one enzyme-controlled carbocation cascade. Synthetic chemists still find this difficult. It is SN1 and carbocation chemistry from CHEM201 carried out with complete control.
Regulation is mostly transcriptional and proteolytic:
- When ER cholesterol is low, the SCAP–SREBP complex moves to the Golgi. There, two proteases release the SREBP transcription factor, which turns on HMG-CoA reductase and LDL receptor genes.
- When sterols are high, Insig retains SCAP in the ER, and HMG-CoA reductase is ubiquitinated and degraded.
- AMPK phosphorylation also inactivates the reductase.
Statins act as competitive inhibitors of HMG-CoA reductase. Lowering intracellular cholesterol activates SREBP, which increases LDL receptor expression and clears LDL from the blood. The drug therefore works through the cell's own feedback system.
Cholesterol is the precursor of:
- bile acids, starting with 7α-hydroxylase;
- steroid hormones, starting with side-chain cleavage to pregnenolone by P450scc in mitochondria. Connect this to BIOL302 endocrinology (cortisol, aldosterone, testosterone, estradiol) and BIOL402 (steroid signaling in development);
- vitamin D.
The isoprenoid pathway also supplies the tail of ubiquinone, dolichol for glycosylation, and farnesyl and geranylgeranyl groups for protein prenylation (see the peptide connections below).
9. Nitrogen Metabolism: Amino Acids, Urea, and Nucleotides
9.1 PLP and transamination
Pyridoxal phosphate (vitamin B₆) is the most versatile cofactor in amino acid metabolism. It catalyzes transamination, decarboxylation, racemization, and β- and γ-eliminations.
The unifying principle. The amino acid replaces an active-site Lys and forms an external aldimine (Schiff base) with PLP. The pyridinium ring is a powerful electron sink. Whichever bond to the α-carbon lies perpendicular to the plane of the PLP π system (Dunathan's stereoelectronic hypothesis) is the one that breaks, because only that orientation lets the resulting carbanion delocalize into the ring as a quinonoid intermediate. The enzyme selects the reaction by how it holds the substrate.
Transamination (ping-pong): amino acid₁ + E-PLP → α-keto acid₁ + E-PMP (pyridoxamine phosphate) α-keto acid₂ + E-PMP → amino acid₂ + E-PLP Typical: amino acid + α-ketoglutarate ⇌ α-keto acid + glutamate (K ≈ 1; fully reversible) ALT: alanine + α-KG ⇌ pyruvate + Glu AST: aspartate + α-KG ⇌ OAA + Glu
Transamination collects amino groups from many amino acids onto glutamate, which acts as the "nitrogen collection point." Glutamate dehydrogenase in liver mitochondria then releases free NH₄⁺:
Glu + NAD(P)⁺ + H₂O ⇌ α-KG + NH₄⁺ + NAD(P)H (GDH; activated by ADP, inhibited by GTP)
Extrahepatic tissues send nitrogen to the liver in non-toxic forms: as glutamine (made by glutamine synthetase) or, from muscle, as alanine (the glucose–alanine cycle).
9.2 The urea cycle
Mitochondrion: NH₄⁺ + HCO₃⁻ + 2 ATP → carbamoyl phosphate (CPS I; ABSOLUTELY requires N-acetylglutamate) carbamoyl-P + ornithine → citrulline (ornithine transcarbamoylase) Cytosol: citrulline + Asp + ATP → argininosuccinate + AMP + PPi (argininosuccinate synthetase; citrullyl-AMP intermediate) argininosuccinate → arginine + fumarate (argininosuccinate lyase) arginine + H₂O → urea + ornithine (arginase) Cost: 3 ATP → 4 phosphoanhydride bonds per urea The two N of urea: one from NH₄⁺ (through carbamoyl-P), one from Asp.
Fumarate links the urea cycle to the TCA cycle, an arrangement called the "Krebs bicycle." Fumarate becomes malate and then OAA, and OAA is transaminated back to aspartate. Recycling aspartate this way cuts the net energy cost, because the reoxidation of malate yields NADH.
Regulation by N-acetylglutamate (NAG). NAG synthase is activated by arginine. When protein breakdown or a high-protein meal raises amino acid levels, arginine rises, NAG rises, and CPS I speeds up. Over longer periods, all five urea cycle enzymes are induced.
Urea cycle defects cause hyperammonemia. Ammonia is neurotoxic, in part because it drains α-KG from the brain's TCA cycle (through GDH and glutamine synthetase) and disrupts glutamate/GABA signaling.
9.3 Carbon skeletons: where amino acids go
After the amino group is removed, the 20 carbon skeletons converge on just seven products: pyruvate, acetyl-CoA, acetoacetyl-CoA, α-KG, succinyl-CoA, fumarate, and OAA.
- Skeletons that become pyruvate or a TCA intermediate are glucogenic. They can produce net OAA, and therefore glucose.
- Those that become acetyl-CoA or acetoacetyl-CoA are ketogenic.
- Leucine and lysine are purely ketogenic. Several, such as Phe, Tyr, Trp, and Ile, are both.
Branched-chain amino acids (Leu, Ile, Val) are catabolized mainly in muscle, not liver, because liver has little branched-chain aminotransferase activity:
- Transamination gives branched-chain α-keto acids.
- The branched-chain α-keto acid dehydrogenase complex (BCKDH) oxidatively decarboxylates them. BCKDH is the third member of the PDC/α-KGDH family: same E3, same cofactor set.
- A defect in BCKDH causes maple syrup urine disease. Branched-chain keto acids build up and give urine its characteristic sweet smell. Untreated, it causes severe neurological damage.
Thiamine-responsive forms exist, as you would expect, since E1 needs TPP.
Phenylalanine:
- Phenylalanine hydroxylase converts Phe to Tyr. It is a mixed-function oxidase that uses O₂ and the cofactor tetrahydrobiopterin.
- Deficiency causes phenylketonuria (PKU). Phe accumulates and is diverted to phenylpyruvate, leading to intellectual disability if untreated.
- Newborn screening combined with a low-Phe diet prevents the damage almost completely, one of medicine's great successes.
- Because Phe hydroxylation is the main source of Tyr, Tyr becomes an essential amino acid in PKU.
- Some patients have defects in biopterin synthesis or regeneration instead. Those forms also affect neurotransmitter synthesis and need different treatment.
Connect this to BIOL102: PKU is the classic autosomal recessive disease and a model of gene–environment interaction.
9.4 Nucleotide biosynthesis
PRPP (5-phosphoribosyl-1-pyrophosphate) is the activated ribose donor for both de novo synthesis and salvage:
ribose-5-P + ATP → PRPP + AMP (PRPP synthetase; ribose-5-P from the PPP)
Purines and pyrimidines are built in opposite orders:
- Purines are built on the sugar. Starting from PRPP, in about ten steps, the ring is assembled atom by atom on the ribose to give IMP. The atoms come from glutamine, glycine, aspartate, CO₂, and two N¹⁰-formyl-THF one-carbon units. IMP then branches to AMP (using GTP) and GMP (using ATP). This cross-use of energy balances the two pools.
- Pyrimidines build the ring first, then attach it. Carbamoyl phosphate (from cytosolic CPS II, which uses glutamine, unlike mitochondrial CPS I) combines with aspartate. In animals, aspartate transcarbamoylase is part of the multifunctional CAD protein. The ring is closed and oxidized to orotate, which is then joined to PRPP to make OMP and decarboxylated to UMP.
Two famous enzymes deserve attention:
- Ribonucleotide reductase converts NDPs to dNDPs using a radical mechanism. A tyrosyl radical (in class I enzymes) produces a thiyl radical that removes the 3′-H. This is real radical chemistry under physiological conditions. Its allosteric regulation is intricate: one site controls overall activity, while a separate specificity site balances the four dNTP pools.
- Thymidylate synthase methylates dUMP to dTMP. N⁵,N¹⁰-methylene-THF serves as both the one-carbon donor and the reductant, leaving dihydrofolate. DHF must be reduced again by dihydrofolate reductase (DHFR). This is the target of methotrexate (which inhibits DHFR) and 5-fluorouracil (whose product forms a covalent dead-end complex with thymidylate synthase). It is the classic logic of cancer chemotherapy: starve rapidly dividing cells of thymidine.
Salvage pathways reuse free bases. HGPRT attaches hypoxanthine or guanine to PRPP. HGPRT deficiency causes Lesch–Nyhan syndrome, with uric acid overproduction and self-injurious behavior. When salvage fails, PRPP accumulates and drives purine synthesis even harder. Purines are degraded to uric acid, and excess uric acid causes gout, which is treated with the xanthine oxidase inhibitor allopurinol.
10. Metabolic Integration: One Body, Many Organs, Two Hormones, One Sensor
10.1 Organ specialization
- Liver: the body's metabolic buffer and processing plant. It handles glucose (glucokinase, glycogen, gluconeogenesis, G6Pase), lipoproteins, ketone production, and urea.
- Skeletal muscle: a large consumer. It stores glycogen for its own use, prefers fatty acids at rest, and relies on glycolysis and phosphocreatine during bursts of activity.
- Brain: glucose-dependent, adapting to ketones only in prolonged starvation. It cannot use fatty acids in a meaningful way.
- Adipose tissue: stores triacylglycerol and releases fatty acids and glycerol. It is also an endocrine organ (leptin, adiponectin).
- Heart: largely aerobic, flexible in fuel choice, mostly fatty acids.
- Red blood cells: glycolysis only, producing lactate.
10.2 Insulin versus glucagon: the master switch
FED STATE: high insulin/glucagon ratio
Insulin → receptor tyrosine kinase → IRS → PI3K → PIP₃ → Akt (PKB)
• GLUT4 translocation (muscle, adipose)
• GSK3 inhibited → glycogen synthase active
• PP1 activated → dephosphorylation of metabolic enzymes
• PDE3B activated → cAMP ↓
• transcription: glucokinase, ACC, FAS ↑ (via SREBP-1c); PEPCK, G6Pase ↓
Net: glycolysis, glycogen synthesis, lipogenesis, protein synthesis ↑
FASTED STATE: low insulin/glucagon ratio
Glucagon → GPCR → cAMP → PKA (liver)
• F2,6BP ↓ → gluconeogenesis ↑
• pyruvate kinase L phosphorylated (off)
• glycogen phosphorylase on, synthase off
• ACC phosphorylated (off) → malonyl-CoA ↓ → CPT1 open → β-oxidation, ketogenesis ↑
• CREB → PEPCK, G6Pase transcription ↑
Adipose (low insulin + catecholamines): hormone-sensitive lipase, ATGL → fatty acid release
A useful rule of thumb in the liver: phosphorylation (by PKA) usually means "fasting mode."
- It turns off glycogen synthase, PFK-2, pyruvate kinase L, and ACC.
- It turns on glycogen phosphorylase and FBPase-2.
There are exceptions, but this rule organizes a great deal of information.
10.3 AMPK: the cell's fuel gauge
AMP-activated protein kinase is a heterotrimer (α catalytic, β scaffold, γ regulatory) [Hardie et al., 2012]. The γ subunit contains CBS domains that bind AMP, ADP, and ATP competitively. AMP binding:
- promotes phosphorylation of α-Thr172 by the upstream kinase LKB1;
- protects that phosphate from phosphatases;
- allosterically activates the enzyme further.
Combined with the adenylate kinase amplifier (Section 1.5), this makes AMPK extremely sensitive to energy stress.
The AMPK rule: turn on ATP-producing pathways, turn off ATP-consuming ones.
- It phosphorylates and inhibits ACC. Malonyl-CoA falls, CPT1 opens, and fatty acid oxidation rises while fatty acid synthesis falls.
- It phosphorylates and inhibits HMG-CoA reductase.
- It promotes GLUT4 translocation in muscle, independently of insulin, which is one reason exercise improves glucose uptake in diabetes.
- It inhibits mTORC1, which slows protein synthesis and growth.
- Over the longer term, it promotes mitochondrial biogenesis through PGC-1α.
Metformin activates AMPK indirectly, apparently by mildly inhibiting mitochondrial respiration and raising AMP. Its full mechanism is still debated.
10.4 Metabolic disease as regulation gone wrong
- Type 1 diabetes: autoimmune destruction of β-cells, which connects to BIOL401. With no insulin, the body acts as if it were fasting even when blood glucose is high. Gluconeogenesis runs, lipolysis runs, and ketoacidosis can follow. It is "starvation in the midst of plenty."
- Type 2 diabetes and metabolic syndrome: insulin resistance (impaired signaling downstream of the receptor in muscle, liver, and adipose tissue) combined with eventual β-cell failure. Ectopic lipid buildup in liver and muscle, through intermediates such as diacylglycerol and ceramides, is strongly implicated.
- An important puzzle is "selective" hepatic insulin resistance. In type 2 diabetes, insulin fails to suppress gluconeogenesis yet still stimulates lipogenesis. That combination produces both hyperglycemia and fatty liver.
- Inborn errors such as PKU, MSUD, urea cycle defects, and glycogen storage diseases. Each one is a natural experiment. The metabolite that builds up upstream of the block, and the shortage downstream of it, reveal how the pathway is wired.
11. Connections to Peptide Chemistry
Metabolism and peptide chemistry meet in more places than you might expect. These connections matter for anyone who later designs, synthesizes, or studies peptides.
11.1 The peptide bond is thermodynamically uphill, so biology pays to activate it
Peptide bond hydrolysis is exergonic (ΔG°′ roughly −10 kJ/mol for a typical bond in water). This means forming a peptide bond from free amino acids is unfavorable. It is the glutamine synthetase problem again (Section 1.3), and biology solves it the same way: activate the carboxyl group.
Aminoacyl-tRNA synthetase: amino acid + ATP → aminoacyl-AMP (mixed carboxylic–phosphoric anhydride) + PPi aminoacyl-AMP + tRNA → aminoacyl-tRNA (ester) + AMP PPi → 2 Pi Ribosome: EF-Tu·GTP delivery + EF-G·GTP translocation Energy per peptide bond ≈ 4 phosphoanhydride bonds (2 from ATP→AMP, 1 GTP for EF-Tu, 1 GTP for EF-G), plus extra GTP for any proofreading/rejection events
This cost is far greater than the bond's thermodynamic requirement. Most of the extra pays for accuracy: kinetic proofreading by synthetases and the ribosome. Protein synthesis is often estimated to be one of the largest ATP consumers in growing cells. Think about that the next time someone calls translation "just" reading a code.
Parallels to solid-phase peptide synthesis (SPPS).
- The aminoacyl-adenylate is a biological mixed anhydride, conceptually the same as the activated esters and anhydrides formed by carbodiimide (DCC/DIC) or uronium (HBTU/HATU) reagents in SPPS.
- The 1,3-BPG acyl phosphate in glycolysis (Section 3.2) is the same type of activated species.
- The energy-rich acyl phosphates, acyl adenylates, and thioesters of metabolism are biology's equivalent of a peptide chemist's coupling reagents.
11.2 Thioesters and swinging arms: nonribosomal peptide synthesis
Fatty acid synthase (Section 8.3) builds chains on a phosphopantetheine arm, holding intermediates as thioesters. Nonribosomal peptide synthetases (NRPS) use exactly the same design to make peptides without a ribosome:
- an adenylation domain makes aminoacyl-AMP;
- a thiolation (peptidyl carrier protein) domain holds the amino acid as a phosphopantetheinyl thioester;
- condensation domains form peptide bonds;
- a thioesterase releases the finished product, often as a cyclic peptide.
Penicillin's precursor (the ACV tripeptide), vancomycin, cyclosporin, and daptomycin are all NRPS products. They often contain D-amino acids and non-proteinogenic residues that the ribosome cannot handle.
If you understand FAS, you already understand the logic of NRPS. Polyketide synthases (erythromycin and others) are the closest relatives of FAS, and hybrid NRPS–PKS assembly lines exist. The thioester also connects to native chemical ligation in synthetic protein chemistry, where a C-terminal peptide thioester reacts with an N-terminal Cys peptide.
11.3 Small peptides made by metabolic enzymes
Glutathione (γ-Glu-Cys-Gly) is assembled by two ATP-dependent ligases through acyl-phosphate intermediates, without a ribosome. Its unusual γ-glutamyl linkage resists ordinary peptidases. Glutathione is the main cellular thiol antioxidant, and it is kept reduced by NADPH from the pentose phosphate pathway (Section 7.4). So a peptide's job depends directly on carbohydrate metabolism.
11.4 Proteins covalently modified by metabolic cofactors and lipids
- Lipoamide (PDC, α-KGDH, BCKDH) and biotin (carboxylases) are attached to Lys ε-amino groups through amide bonds. Specific ligases add them, which is post-translational modification by metabolic cofactors.
- Protein prenylation. Farnesyl (C₁₅) and geranylgeranyl (C₂₀) groups from the cholesterol pathway are attached to C-terminal CaaX cysteines (in Ras, for example), which anchors these proteins to membranes. Statins therefore affect protein localization as well as cholesterol levels.
- Acylation. N-myristoylation and S-palmitoylation use fatty acyl-CoAs from lipid metabolism.
- Lysine acetylation. Acetyl-CoA levels directly affect protein and histone acetylation, linking metabolic state to gene expression (connect to BIOL201).
11.5 Peptide hormones: metabolic regulators as drugs
The two master regulators in Section 10 are peptides:
- Insulin: A chain of 21 residues and B chain of 30, joined by two interchain disulfides plus one intrachain disulfide. It is processed from proinsulin, and removing the C-peptide is diagnostically useful.
- Glucagon: 29 residues.
Modern peptide therapeutics are largely metabolic drugs:
- Insulin analogs with altered kinetics, such as lispro (the B28/B29 Pro-Lys swap reduces hexamer formation) or acylated long-acting forms.
- GLP-1 receptor agonists, such as semaglutide. Its design applies peptide chemistry to metabolism directly:
- a non-proteinogenic Aib residue at position 2 blocks cleavage by dipeptidyl peptidase-4;
- a fatty diacid side chain attached through a linker binds serum albumin, extending its half-life to about a week.
Understanding why GLP-1 signaling lowers glucose (glucose-dependent insulin secretion, glucagon suppression, slower gastric emptying) requires the metabolic integration from this course. Understanding how the molecule survives in blood requires peptide chemistry.
11.6 Amino acid supply sets peptide synthesis
Essential amino acids, mTORC1 sensing of leucine and arginine, AMPK's inhibition of mTORC1, and the transamination network together determine whether a cell has the building blocks and the "permission" to make proteins. When you later study peptide synthesis, cellular or synthetic, remember that the supply chain for monomers is a metabolic question.
12. Common Misconceptions to Watch Out For
- "ATP contains a high-energy bond that releases energy when broken." Breaking any bond costs energy. The free energy of ATP hydrolysis comes from the whole reaction: product stabilization (resonance, solvation, ionization) and charge separation. Most importantly, in cells the large ΔG comes from keeping [ATP]/[ADP][Pi] far from equilibrium. The squiggle "~P" is shorthand, not physics.
- "ΔG°′ tells you whether a reaction goes forward in the cell." Aldolase (+23.8 kJ/mol) and malate dehydrogenase (+29.7 kJ/mol) both run forward in vivo, because product concentrations are kept low. Always reason with the actual ΔG.
- "Each glucose gives exactly 36 or 38 ATP." Modern values are about 30–32. The number is not an integer, and it varies with the shuttle used, proton leak, and the c-ring stoichiometry. The chemiosmotic coupling has no fixed integer ratio.
- "ATP synthase uses proton energy to form the bond between ADP and Pi." In Boyer's mechanism, ATP forms spontaneously in the tight site. The energy is spent changing binding affinities, mainly to release ATP [Boyer, 1997].
- "The TCA cycle uses oxygen." It uses none directly. It needs O₂ only indirectly, because NAD⁺ and FAD are regenerated by the electron transport chain.
- "Animals can turn fat into glucose." Not from even-chain fatty acids. PDC is irreversible, and the TCA cycle releases two CO₂ for every acetyl-CoA. The glycerol backbone and odd-chain propionyl-CoA are minor exceptions. Isotope labels from acetyl-CoA can appear in glucose by exchange through the cycle, but there is no net synthesis, a classic trick question.
- "There is one rate-limiting step per pathway." Control is usually shared among several enzymes (metabolic control analysis). "Committed step" and "major control point" are useful terms, but overexpressing one enzyme rarely increases flux much on its own.
- "Lactate is a waste product that causes muscle soreness." Lactate is a major fuel and gluconeogenic substrate, moved between tissues (the Cori cycle and lactate shuttles). Delayed-onset soreness comes from muscle microdamage and inflammation, not lactate. The acidosis during intense exercise comes mainly from ATP hydrolysis and the overall balance of glycolytic proton production, not from lactate itself.
- "Glycolysis is the anaerobic pathway." Glycolysis runs in both conditions. Only the fate of pyruvate and NADH depends on oxygen. Many cancer cells and fast-dividing cells use glycolysis heavily even with oxygen present (the Warburg effect), partly to supply biosynthetic precursors.
- "NADH and NADPH are interchangeable." They are separate pools kept at very different redox ratios, and enzymes are highly specific for one or the other. NADH serves catabolism and ATP production, NADPH serves biosynthesis and antioxidant defense.
- "Ketone bodies are pathological." Ketosis is a normal, protective response to fasting that preserves muscle. Ketoacidosis, mainly in uncontrolled type 1 diabetes, is the pathology.
- "Phosphorylation always activates an enzyme." PKA phosphorylation activates glycogen phosphorylase but inactivates glycogen synthase, PDH, ACC, and liver pyruvate kinase. The meaning depends entirely on the enzyme. What phosphorylation does is coordinate opposing pathways.
- "Insulin just lowers blood sugar." Insulin is a broad anabolic hormone. It promotes glycogen, fat, and protein synthesis and suppresses lipolysis, ketogenesis, and gluconeogenesis. Many diabetic complications reflect this broader role.
- "Electrons flow through the chain because each carrier 'wants' them more." That is roughly right but incomplete. Flow is set by reduction potentials and by distances and geometry (tunneling rates). The chain also includes uphill steps (some Fe–S clusters in Complex I), which work because the next steps pull electrons onward. The overall drop in potential drives the flow, not each individual step.
13. A Closing Thought
Taken together, the course reduces to a small set of organizing ideas:
- Energy is captured in a few currencies (ATP, reduced carriers, and the proton gradient) by coupling favorable processes to unfavorable ones through shared intermediates.
- Chemistry is a limited set of reaction types, reused with cofactors that act as electron sinks or carriers: TPP, PLP, biotin, lipoamide, FAD, NAD(P)⁺, CoA, and THF.
- Pathway design places control at the irreversible steps and makes opposing pathways differ in compartment, cofactor, and stereochemistry so they can be regulated separately.
- Regulation combines several layers: allosteric signals that act in seconds (amplified, as with AMP), covalent modification over minutes (PKA, AMPK, phosphatases), and gene expression over hours (SREBP, CREB).
- Integration across organs is managed by two peptide hormones and one energy-sensing kinase.
Peter Mitchell's insight that a membrane can store energy, and Boyer's insight that a rotating protein can convert that stored energy into chemical bonds, are among the deepest ideas in biology. They show that physics, chemistry, and evolution together built a molecular motor of near-perfect efficiency. Keep that in mind when the charts feel overwhelming.
References
- Abrahams, J. P., Leslie, A. G. W., Lutter, R., & Walker, J. E. (1994). Structure at 2.8 Å resolution of F₁-ATPase from bovine heart mitochondria. Nature, 370, 621–628.
- Atkinson, D. E. (1968). The energy charge of the adenylate pool as a regulatory parameter. Interaction with feedback modifiers. Biochemistry, 7, 4030–4034.
- Berg, J. M., Tymoczko, J. L., Gatto, G. J., & Stryer, L. (2019). Biochemistry (9th ed.). W. H. Freeman.
- Boyer, P. D. (1997). The ATP synthase—a splendid molecular machine. Annual Review of Biochemistry, 66, 717–749. DOI: 10.1146/annurev.biochem.66.1.717. (Listed in the course materials as "The Rotary Mechanism of ATP Synthase.")
- Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012). AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nature Reviews Molecular Cell Biology, 13, 251–262.
- Kacser, H., & Burns, J. A. (1973). The control of flux. Symposia of the Society for Experimental Biology, 27, 65–104.
- Mitchell, P. (1961). Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature, 191, 144–148.
- Nelson, D. L., & Cox, M. M. (2021). Lehninger Principles of Biochemistry (8th ed.). W. H. Freeman.
- Noji, H., Yasuda, R., Yoshida, M., & Kinosita, K., Jr. (1997). Direct observation of the rotation of F₁-ATPase. Nature, 386, 299–302.
Verification note: numerical values (ΔG°′, E°′, stoichiometries) follow Lehninger 8th ed. Small differences from Stryer 9th ed. reflect rounding or experimental conditions. Check your edition's tables before an exam.
⚙️ Mechanisms & Applications
Mechanisms & Applications: Following Matter, Electrons, and Free Energy
Skipper’s organizing principle: a metabolic pathway is not merely a sequence of compounds. It is a controlled route for moving carbon atoms, electrons, nitrogen, and free energy. For every pathway, I should ask: What chemical problem is being solved? What drives the solution? Where does it happen? What prevents it from running at the wrong time?
CHEM201–202 supplied the reaction vocabulary: nucleophilic attack, carbonyl chemistry, enolates, acyl transfer, and oxidation–reduction. CHEM301 supplied the thermodynamic constraints. CHEM401 supplied the molecular machinery. This course joins those ideas into an operating cell. The most useful habit is to track atoms, electrons, energy, and regulation separately, then reconcile all four accounts. [1,2]
1. Coupling Reactions: ATP Is Not a Packet of Energy
The phrase “energy-rich bond” can conceal the chemistry. Breaking a bond requires energy; ATP hydrolysis is favorable because the complete reaction produces species with more favorable hydration, electrostatic interactions, and resonance stabilization. ATP’s usefulness lies in its intermediate phosphoryl-transfer potential and in enzymes’ ability to connect its reactions to otherwise unfavorable processes.
Actual reaction free energy: ΔG = ΔG°′ + RT ln Q At equilibrium: ΔG = 0 ΔG°′ = −RT ln K′ Coupled reactions: ΔGtotal = ΔG1 + ΔG2 ATP + H2O → ADP + Pi ΔG°′ ≈ −30.5 kJ mol−1 Inside cells, ATP hydrolysis is often substantially more favorable, commonly around −45 to −60 kJ mol−1, depending on conditions.
The prime indicates a biochemical transformed standard state, conventionally defined at a specified pH, often pH 7. Concentrations, Mg2+ binding, ionic strength, and temperature matter when applying these values. Strictly, the reaction quotient contains dimensionless activities, not bare concentrations.
Mechanistic example: hexokinase does not hydrolyze ATP beside glucose and hope the released energy helps. It binds both substrates, closes around them, activates the glucose 6-hydroxyl group, and transfers ATP’s terminal phosphoryl group directly to glucose. Mg2+ helps organize and stabilize the nucleotide’s negative charges.
Unfavorable phosphorylation: Glucose + Pi → glucose 6-phosphate + H2O Favorable ATP hydrolysis: ATP + H2O → ADP + Pi Enzyme-coupled net reaction: Glucose + ATP → glucose 6-phosphate + ADP
The important distinction: adding two equations proves thermodynamic feasibility; identifying a shared intermediate or an enzyme-mediated transfer explains actual coupling. The same logic applies to aminoacyl-tRNA synthesis, fatty acid activation, and peptide manufacturing with ATP-dependent ligases.
NADH and NADPH are another example of chemical similarity serving different physiological roles. Both transfer hydride equivalents, but cells generally maintain NAD+/NADH pools suitable for substrate oxidation and NADPH/NADP+ pools suitable for reductive biosynthesis and antioxidant defense. Their phosphate difference is chiefly an enzyme-recognition handle, not a fundamentally different reducing chemistry. [1,2]
2. Glycolysis: Making a Stable Sugar Yield ATP
Glycolysis solves three linked problems: retain glucose inside the cell, split a six-carbon molecule into useful three-carbon units, and convert oxidation energy into ATP. Its chemistry becomes easier to understand when the first five reactions are viewed as preparation and the last five as energy recovery.
- Hexokinase: glucose → glucose 6-phosphate. ATP-dependent phosphoryl transfer traps glucose in a charged form and prepares it for further chemistry. Most hexokinases are inhibited by glucose 6-phosphate. Hepatic glucokinase is a distinct isozyme with different kinetics and regulation.
- Phosphoglucose isomerase: glucose 6-phosphate → fructose 6-phosphate. Ring opening and acid–base catalysis through an enediol/enediolate intermediate move the carbonyl from C1 to C2. This positioning makes the later cleavage yield two three-carbon products.
- Phosphofructokinase-1, PFK-1: fructose 6-phosphate → fructose 1,6-bisphosphate. A second ATP-dependent phosphorylation commits carbon strongly toward glycolysis. ATP is both a substrate and, at higher concentrations, an allosteric inhibitor. AMP and fructose 2,6-bisphosphate favor activity; citrate can reinforce inhibition.
- Aldolase: fructose 1,6-bisphosphate → glyceraldehyde 3-phosphate plus dihydroxyacetone phosphate. Mammalian class I aldolase forms a Schiff base with an active-site lysine, using the imine as an electron sink during C–C bond cleavage. Many microbial class II aldolases instead use a metal ion.
- Triose phosphate isomerase: dihydroxyacetone phosphate ⇌ glyceraldehyde 3-phosphate through an enediol(ate) intermediate. Consumption of glyceraldehyde 3-phosphate pulls the reaction toward supplying a second copy of the same downstream substrate.
- Glyceraldehyde 3-phosphate dehydrogenase: an active-site cysteine attacks the aldehyde; oxidation transfers hydride to NAD+, forming an enzyme-bound thioester. Inorganic phosphate attacks that thioester to make 1,3-bisphosphoglycerate. Oxidation energy is thereby conserved in an acyl phosphate rather than simply dissipated.
- Phosphoglycerate kinase: 1,3-bisphosphoglycerate transfers a phosphoryl group to ADP, producing ATP and 3-phosphoglycerate. This is substrate-level phosphorylation.
- Phosphoglycerate mutase: 3-phosphoglycerate → 2-phosphoglycerate. The mammalian enzyme uses phosphohistidine and a transient 2,3-bisphosphoglycerate intermediate to relocate the phosphate.
- Enolase: dehydration produces phosphoenolpyruvate, PEP. Mg2+ stabilizes the carbanion-like intermediate. The product has unusually high phosphoryl-transfer potential because its dephosphorylated enol can tautomerize to a stable ketone.
- Pyruvate kinase: PEP transfers phosphate to ADP, then enolpyruvate becomes pyruvate. Tautomerization helps make the overall reaction strongly favorable. Fructose 1,6-bisphosphate provides feed-forward activation in relevant isozymes; hepatic pyruvate kinase is inhibited by glucagon-triggered phosphorylation.
Per glucose: Glucose + 2 NAD+ + 2 ADP + 2 Pi → 2 pyruvate + 2 NADH + 2 ATP + 2 H2O + 2 H+ ATP account: 2 ATP invested 4 ATP produced Net = 2 ATP Lactate dehydrogenase: Pyruvate + NADH + H+ ⇌ lactate + NAD+ Purpose of lactate production: Regenerate NAD+ so glyceraldehyde 3-phosphate dehydrogenase can continue.
Counterintuitive point: lactate production is not a separate way of obtaining extra ATP from pyruvate. It maintains the redox conditions that allow glycolysis to keep producing ATP. Lactate is also a circulating fuel and gluconeogenic precursor, not merely waste, and its production is not restricted to oxygen-free conditions.
Medical application: mature erythrocytes have no mitochondria, so glycolysis supplies their ATP. Pyruvate kinase deficiency can therefore destabilize erythrocyte ion homeostasis and cause hemolytic anemia. In oncology, 18F-fluorodeoxyglucose PET exploits glucose uptake and hexokinase-dependent trapping, although increased tracer uptake is not cancer-specific: activated immune tissues can also be strongly positive. [1,2]
3. Pyruvate Dehydrogenase: A Multienzyme Assembly Line
Pyruvate dehydrogenase, PDH, makes the major mammalian bridge from carbohydrate breakdown to acetyl-CoA oxidation. Its five coenzymes divide a difficult oxidative decarboxylation into manageable chemical tasks. The lipoyl group is a covalently tethered “swinging arm,” carrying intermediates between active sites rather than releasing them into solution.
- E1, pyruvate dehydrogenase, with thiamine pyrophosphate: TPP attacks pyruvate and facilitates decarboxylation. Its thiazolium ring stabilizes the resulting hydroxyethyl carbanion equivalent.
- Transfer to the E2 lipoyl group: the hydroxyethyl fragment is oxidized to an acetyl group while the lipoyl disulfide is reduced. The acetyl group is retained as a thioester.
- E2, dihydrolipoyl transacetylase: CoA accepts the acetyl group, producing acetyl-CoA.
- E3, dihydrolipoyl dehydrogenase: the reduced lipoyl group is reoxidized through an enzyme disulfide and FAD.
- NAD+ restores oxidized E3: reducing equivalents pass from reduced FAD to NAD+, generating NADH.
Pyruvate + CoA-SH + NAD+ → acetyl-CoA + CO2 + NADH + H+ Coenzyme roles: TPP carbon–carbon bond cleavage and carbanion stabilization Lipoamide acyl-group and electron transport CoA acyl-group acceptance FAD enzyme-bound redox relay NAD+ diffusible electron acceptor
Regulation: PDH kinase phosphorylates and inhibits E1; PDH phosphatase reverses that inhibition. High-energy and product-rich conditions favor reduced PDH activity. Pyruvate inhibits PDH kinase, while Ca2+ activates PDH phosphatase in working muscle, linking contraction to fuel oxidation.
Clinical connection: thiamine deficiency impairs PDH and other TPP-dependent enzymes, including α-ketoglutarate dehydrogenase and branched-chain α-ketoacid dehydrogenase. Pyruvate can be diverted toward lactate, while vulnerable tissues experience impaired oxidative ATP production. Arsenite can inhibit reduced lipoyl-containing enzyme systems by interacting with their vicinal thiols.
Boundary to remember: mammals cannot reverse PDH to obtain pyruvate from acetyl-CoA. This helps explain why even-chain fatty acids cannot provide net glucose carbon. [1,2]
4. The TCA Cycle: Oxidation Through a Regenerated Acceptor
Oxaloacetate is not simply the “first substrate” of the TCA cycle. It is a regenerated acceptor that enables acetyl-group oxidation. The cycle is also amphibolic: its intermediates are continuously borrowed for biosynthesis. A functioning cycle therefore requires both oxidation and replenishment.
- Citrate synthase: an acetyl-CoA enolate attacks oxaloacetate; hydrolysis of the resulting citryl-CoA thioester drives citrate formation.
- Aconitase: dehydration and rehydration through cis-aconitate reposition the hydroxyl group, converting citrate to isocitrate. An iron–sulfur cluster helps bind and orient the substrate.
- Isocitrate dehydrogenase: oxidation forms oxalosuccinate, a β-ketoacid intermediate that decarboxylates to α-ketoglutarate. The canonical mitochondrial cycle uses the NAD+-dependent enzyme IDH3.
- α-Ketoglutarate dehydrogenase: PDH-like oxidative decarboxylation forms succinyl-CoA, CO2, and NADH using TPP, lipoamide, CoA, FAD, and NAD+.
- Succinyl-CoA synthetase: thioester energy is conserved through succinyl phosphate and phosphohistidine intermediates, yielding GTP or ATP depending on the isozyme.
- Succinate dehydrogenase: oxidation of succinate to fumarate reduces bound FAD; electrons then pass through iron–sulfur centers to ubiquinone. This enzyme is also respiratory Complex II.
- Fumarase: stereospecific addition of water converts fumarate to L-malate.
- Malate dehydrogenase: malate oxidation regenerates oxaloacetate and NADH. Although its standard free-energy change is unfavorable, low oxaloacetate concentration, maintained partly by citrate synthase, permits forward flux.
Per acetyl-CoA oxidized: 3 NADH 1 pair of electrons delivered to Q through Complex II 1 GTP or ATP 2 CO2 Approximate oxidative energy equivalent: 3(2.5 ATP) + 1(1.5 ATP) + 1 ATP = 10 ATP Major anaplerotic reaction: Pyruvate + HCO3− + ATP → oxaloacetate + ADP + Pi Enzyme: pyruvate carboxylase Cofactor: biotin Activator: acetyl-CoA
The two carbons entering as acetyl-CoA are generally not the carbons released in that same first turn. Carbon-labeling experiments reveal this immediately and prevent the misleading picture that each turn simply burns its newly added acetyl group.
Application to cancer biochemistry: some mutant IDH1 or IDH2 enzymes acquire the ability to reduce α-ketoglutarate to D-2-hydroxyglutarate using NADPH. This oncometabolite interferes with α-ketoglutarate-dependent dioxygenases, connecting metabolism to chromatin regulation and differentiation. These enzymes must not be confused with the canonical NAD-dependent TCA enzyme IDH3. [1,2]
5. Respiration: Converting Electron Flow into a Proton Gradient
The respiratory chain is an electrochemical transducer. Electron transfer becomes ATP production only because selected redox steps are coupled to directional proton movement across a membrane.
Redox driving force: ΔG°′ = −nFΔE°′ ΔE°′ = E°′electron acceptor − E°′electron donor For NADH oxidation by O2: ΔE°′ ≈ 0.82 − (−0.32) = 1.14 V n = 2 ΔG°′ ≈ −220 kJ mol−1 NADH
- Complex I: a membrane-associated, L-shaped assembly transfers electrons from NADH through FMN and iron–sulfur centers to ubiquinone, Q. Quinone reduction is coupled through conformational and electrostatic changes to proton translocation in membrane modules, including antiporter-like subunits. The usual accounting is 4 H+ pumped per electron pair.
- Complex II: transfers succinate-derived electrons through FAD and iron–sulfur centers to Q. It does not pump protons, so this entry point yields less ATP.
- Ubiquinone: a membrane-soluble carrier that accepts two electrons and two protons to form QH2. It connects several dehydrogenases to Complex III.
- Complex III: the dimeric cytochrome bc1 complex uses a Q cycle. At the Qo site, one electron from QH2 travels through the Rieske iron–sulfur center and cytochrome c1 to cytochrome c; the other traverses b hemes toward the Qi site. Two turnovers generate net translocation equivalent to 4 H+ per electron pair delivered to cytochrome c.
- Cytochrome c: a small, soluble protein on the outer face of the inner mitochondrial membrane. Its heme carries one electron at a time.
- Complex IV: electrons pass through copper and heme centers to the heme a3–CuB oxygen-reduction site. For each electron pair, it pumps about 2 H+ and consumes an additional 2 matrix protons in water formation. Chemical proton consumption and proton pumping are distinct parts of the bookkeeping.
Approximate protons translocated per electron pair: NADH → I → Q → III → cytochrome c → IV → O2 4 + 4 + 2 = 10 H+ Succinate → II → Q → III → cytochrome c → IV → O2 0 + 4 + 2 = 6 H+
Mechanistic humility: net stoichiometry is better established than every microscopic coupling step, especially in Complex I. A good explanation should distinguish a robust proton count from an evolving atomic-level model. [1,2]
6. ATP Synthase: Chemistry Driven by Rotation
ATP synthase turns the membrane’s electrochemical potential into mechanical rotation and then into altered substrate affinities. Boyer’s binding-change model made a surprising proposal: a crucial energy-requiring task is not simply making the ATP bond, but changing catalytic conformations so tightly bound ATP can be released.
- Protons enter an aqueous half-channel in the membrane-embedded Fo a subunit.
- A proton binds a conserved acidic residue on a c-ring subunit, allowing that site to move into the hydrophobic membrane environment.
- Rotation brings the site to a second half-channel, where the proton exits toward the matrix.
- The c ring turns the central stalk, including the γ subunit, relative to the stationary α3β3 catalytic head.
- Successive β-subunit conformations bind ADP and Pi, favor ATP formation, and release ATP. One full rotation gives three catalytic ATP-producing events.
Free energy for one proton moving from outside to matrix:
ΔGinward = RT ln([H+]matrix/[H+]outside)
+ F(ψmatrix − ψoutside)
Both a relatively alkaline matrix and a negative matrix
favor inward proton movement.
Useful magnitude:
|ΔG per mol H+| = F × |proton-motive force|
At |proton-motive force| = 0.18 V:
|ΔG| ≈ 17.4 kJ mol−1 H+
Rotor stoichiometry:
H+ through Fo per ATP = number of c subunits / 3
For a mammalian c8 ring:
H+/ATP = 8/3 ≈ 2.67 through ATP synthase itself.
This rotor ratio is not the complete energetic cost of delivering ATP to the cytosol. Phosphate uptake, electrogenic ADP/ATP exchange, proton leak, and other uses of the gradient alter effective efficiency. The conventional working P/O values are approximately 2.5 ATP per NADH-linked electron pair and 1.5 per Q-linked pair; they are useful estimates, not immutable integer yields. Here P/O refers to ATP formed per oxygen atom reduced, equivalent to one electron pair reducing half an O2.
Experimental and historical connection: Peter Mitchell proposed chemiosmotic coupling in 1961, replacing the search for a universal high-energy chemical intermediate with a membrane-gradient mechanism. Boyer developed the binding-change model, structural work led by John Walker clarified the catalytic architecture, and Noji and colleagues directly visualized ATP-driven F1 rotation in 1997 using a fluorescent actin filament attached to the rotor. That experiment demonstrated the reversible motor operating in the ATP-hydrolysis direction. [3–5]
Medical applications: cyanide inhibits Complex IV, whereas oligomycin inhibits ATP synthase’s proton-conducting machinery. An uncoupler can increase oxygen consumption while decreasing ATP yield by dissipating the gradient. Physiological UCP1-dependent uncoupling in brown adipose tissue produces heat; uncontrolled chemical uncoupling can produce fatal hyperthermia. Oxygen consumption is therefore not synonymous with ATP production.
7. Gluconeogenesis and Glycogen: Reciprocal Control Prevents Waste
Gluconeogenesis is not glycolysis played backward. It reuses near-equilibrium reactions but bypasses strongly favorable glycolytic steps with different enzymes and additional energy input.
Glycolytic step Gluconeogenic bypass Pyruvate kinase Pyruvate carboxylase, then PEPCK PFK-1 Fructose 1,6-bisphosphatase Hexokinase/glucokinase Glucose 6-phosphatase From 2 pyruvate to 1 glucose: Consumes 4 ATP + 2 GTP + 2 NADH
Pyruvate carboxylase first makes oxaloacetate in mitochondria. Because oxaloacetate does not freely cross the inner membrane, carbon may travel through malate, aspartate, or PEP, depending on substrate and tissue context. PEP carboxykinase uses GTP-dependent decarboxylation–phosphorylation to form PEP. The temporary addition and later loss of CO2 make the difficult pyruvate-to-PEP conversion feasible.
Fructose 2,6-bisphosphate is a regulatory signal, not a glycolytic intermediate. It activates PFK-1 and inhibits fructose 1,6-bisphosphatase. In liver, glucagon → cAMP → protein kinase A phosphorylates the hepatic PFK-2/FBPase-2 bifunctional enzyme, lowering fructose 2,6-bisphosphate and favoring gluconeogenesis. This phosphorylation response is isoform-specific and should not be generalized to every tissue.
Glycogen assembly and mobilization:
- Glucose 1-phosphate reacts with UTP to form UDP-glucose; pyrophosphate hydrolysis helps drive activation.
- Glycogenin supplies the classical primer, and glycogen synthase extends α(1→4) chains at nonreducing ends.
- Branching enzyme transfers chain segments to create α(1→6) branches, increasing solubility and the number of accessible ends.
- Glycogen phosphorylase uses Pi to release glucose 1-phosphate from α(1→4) linkages. This is phosphorolysis, conserving a phosphorylation that free glucose would otherwise require.
- Debranching enzyme combines transferase and α(1→6)-glucosidase activities to clear branch points.
Glucagon acts chiefly on liver rather than skeletal muscle; epinephrine can mobilize glycogen in both. PKA activates phosphorylase kinase, which activates glycogen phosphorylase. Ca2+–calmodulin also stimulates phosphorylase kinase during muscle contraction. Liver can release free glucose through its glucose 6-phosphatase system; skeletal muscle lacks that capacity and retains glycogen carbon for local use.
Quantitative application—the Cori cycle: conversion of one glucose to two lactates yields 2 ATP in glycolytic tissue, whereas rebuilding glucose from those lactates costs the liver 6 high-energy phosphate equivalents. The organism spends a net 4 equivalents to relocate metabolic work. This is useful division of labor, not a thermodynamic mistake. [1,2]
8. The Pentose Phosphate Pathway: Reducing Power and Carbon Rearrangement
- Glucose 6-phosphate dehydrogenase oxidizes glucose 6-phosphate and generates NADPH.
- Lactonase hydrolyzes the resulting lactone.
- 6-Phosphogluconate dehydrogenase performs oxidative decarboxylation, yielding ribulose 5-phosphate, CO2, and a second NADPH.
- Isomerase and epimerase reactions supply ribose 5-phosphate and xylulose 5-phosphate.
- Transketolase, using TPP, transfers two-carbon units; transaldolase, using a lysine Schiff base, transfers three-carbon units. These reversible reactions connect pentose demand to glycolytic intermediates.
Oxidative branch, per glucose 6-phosphate:
2 NADPH + 1 CO2 + 1 ribulose 5-phosphate
Nonoxidative carbon balance:
3 pentose phosphates ⇌ 2 fructose 6-phosphate
+ 1 glyceraldehyde 3-phosphate
Antioxidant connection:
GSSG + NADPH + H+ → 2 GSH + NADP+
Enzyme: glutathione reductase
Clinical application: erythrocytes rely heavily on this pathway to maintain reduced glutathione. In G6PD deficiency, infections, fava beans, and certain oxidant drugs can overwhelm antioxidant capacity and trigger hemolysis. The mechanistic lesion is insufficient reductive defense, not primarily a failure of glycolytic ATP production.
Bioprocess application: production strains making reduced products often require increased NADPH supply. Engineering the pentose phosphate pathway can help, but oxidative NADPH generation loses carbon as CO2. High reducing-power supply and high carbon yield are not automatically the same objective. [1,2]
9. Fatty Acid Oxidation and Synthesis: Separate Machines, Opposite Purposes
Oxidation begins before the four-step spiral. Acyl-CoA synthetase activates a fatty acid through an acyl-adenylate intermediate. Because ATP becomes AMP and pyrophosphate, and pyrophosphate is hydrolyzed, activation costs two high-energy phosphate equivalents.
Long-chain acyl groups enter mitochondria through the carnitine shuttle: CPT I forms acylcarnitine, a translocase exchanges it across the inner membrane, and CPT II regenerates matrix acyl-CoA. Carnitine transports the acyl group, not CoA itself.
One β-oxidation cycle: 1. Acyl-CoA dehydrogenase: Acyl-CoA → trans-Δ2-enoyl-CoA Electrons → FAD → ETF → ETF:Q oxidoreductase → Q 2. Enoyl-CoA hydratase: Add H2O → L-3-hydroxyacyl-CoA 3. 3-Hydroxyacyl-CoA dehydrogenase: NAD+-dependent oxidation → 3-ketoacyl-CoA + NADH 4. β-Ketothiolase: CoA-dependent cleavage → acetyl-CoA + acyl-CoA shortened by two carbons Palmitate, C16: 7 cycles → 8 acetyl-CoA + 7 NADH + 7 Q-linked electron pairs Approximate net ATP: 8(10) + 7(2.5) + 7(1.5) − 2 = 106 ATP
Do not route all “FADH2” through Complex II. β-Oxidation electrons reach Q through electron-transfer flavoprotein, ETF, and ETF:Q oxidoreductase. “FADH2 yield” is convenient energy shorthand, not a freely diffusing mitochondrial metabolite.
Ketogenesis: in liver mitochondria, acetyl-CoA is converted through acetoacetyl-CoA and HMG-CoA to acetoacetate; reduction produces β-hydroxybutyrate. During fasting, fatty acid oxidation supplies energy while oxaloacetate availability and gluconeogenic demand constrain acetyl-CoA oxidation. Exported ketone bodies provide other tissues with fuel. Liver lacks SCOT, the key enzyme required for conventional ketone-body utilization, so it exports what it cannot itself efficiently consume.
Synthesis uses different chemistry and compartmentation:
- Citrate export and ATP-citrate lyase supply cytosolic acetyl-CoA.
- Biotin-dependent acetyl-CoA carboxylase, ACC, uses ATP to produce malonyl-CoA.
- Fatty acid synthase loads acetyl and malonyl groups onto its catalytic sites and acyl carrier protein, ACP.
- Decarboxylative condensation extends the chain by two carbons. The CO2 added by ACC is lost here; it activates the donor rather than remaining in the product.
- NADPH-dependent reduction, dehydration, and a second NADPH-dependent reduction complete each elongation cycle.
Palmitate synthesis from cytosolic acetyl-CoA: 8 acetyl-CoA + 7 ATP + 14 NADPH are required. This excludes upstream costs of delivering acetyl units to the cytosol. Reciprocal control: Malonyl-CoA inhibits CPT I. AMPK phosphorylates and inhibits ACC: ↓ fatty acid synthesis ↓ malonyl-CoA Reduced inhibition of mitochondrial fatty acid entry
Clinical application: medium-chain acyl-CoA dehydrogenase deficiency can cause fasting-induced hypoketotic hypoglycemia. Impaired fatty acid oxidation limits both energy support for gluconeogenesis and ketone production. The combination of low glucose and inappropriately low ketones is more informative than either measurement alone. [1,2]
10. Cholesterol, Isoprenoids, and Drug Targets
Cholesterol synthesis turns acetyl-CoA into activated five-carbon building blocks, then into a highly organized four-ring structure.
Acetyl-CoA → acetoacetyl-CoA → HMG-CoA → mevalonate → activated isoprene units → geranyl pyrophosphate → farnesyl pyrophosphate → squalene → squalene epoxide → lanosterol → cholesterol HMG-CoA reductase: HMG-CoA + 2 NADPH + 2 H+ → mevalonate + CoA-SH + 2 NADP+
The reductase is an ER membrane protein with a cytosolic catalytic domain. Do not confuse this pathway with mitochondrial HMG-CoA formation during ketogenesis. Same intermediate name; different compartments and purposes.
Statins inhibit HMG-CoA reductase. Lower hepatic cholesterol promotes SREBP-dependent responses, including increased LDL receptor expression, enhancing clearance of circulating LDL. Thus a drug targeting synthesis lowers plasma LDL partly by changing receptor-mediated uptake. Mevalonate-derived isoprenoids also support protein prenylation, ubiquinone synthesis, and dolichol formation; the pathway makes more than cholesterol.
Cholesterol supplies steroid hormones and bile acids. Steroidogenic tissues use mitochondrial CYP11A1 to initiate conversion to pregnenolone, while bile-acid synthesis provides an important route for cholesterol disposal.
Historical connection: Akira Endo’s fungal natural-product screening identified compactin-related cholesterol-synthesis inhibitors in the 1970s, establishing the statin strategy. Brown and Goldstein’s work on LDL receptors explained why intracellular synthesis and extracellular lipoprotein clearance must be understood together. [1,2,8]
11. Amino Acid Nitrogen: Move It Safely, Then Dispose of It
Amino acid catabolism presents two different problems: recovering useful carbon and handling potentially toxic nitrogen. Transamination separates those tasks without initially releasing free ammonia.
- A PLP-dependent aminotransferase replaces its enzyme–PLP internal aldimine with a substrate–PLP external aldimine.
- PLP’s conjugated system stabilizes electron redistribution during proton transfer.
- Rearrangement and hydrolysis release an α-ketoacid, leaving pyridoxamine phosphate, PMP.
- A second α-ketoacid, often α-ketoglutarate, accepts the amino group, regenerating PLP and producing glutamate.
Typical transamination: Amino acid + α-ketoglutarate ⇌ corresponding α-ketoacid + glutamate Oxidative deamination: Glutamate + NAD(P)+ + H2O ⇌ α-ketoglutarate + NH4+ + NAD(P)H + H+
Glutamine and alanine help transport nitrogen between tissues. In liver, nitrogen reaches the urea cycle as ammonia/ammonium and aspartate.
- Carbamoyl phosphate synthetase I, mitochondria: uses ammonia, bicarbonate, and 2 ATP. N-acetylglutamate is an obligatory activator; arginine stimulates its synthesis.
- Ornithine transcarbamylase, mitochondria: transfers the carbamoyl group to ornithine, generating citrulline for export to the cytosol.
- Argininosuccinate synthetase, cytosol: adds aspartate to citrulline using ATP → AMP + PPi.
- Argininosuccinate lyase: produces arginine and fumarate.
- Arginase: hydrolyzes arginine to urea and ornithine, completing the cycle.
Urea nitrogen sources: 1 nitrogen from ammonia 1 nitrogen from aspartate Urea carbon source: Bicarbonate Energy cost: 3 ATP molecules consumed 4 high-energy phosphate bonds expended
Carbon skeletons enter metabolism as pyruvate, acetyl-CoA, acetoacetate, α-ketoglutarate, succinyl-CoA, fumarate, or oxaloacetate. Leucine and lysine are exclusively ketogenic; other amino acids are glucogenic or both glucogenic and ketogenic.
- Phenylketonuria: usually reflects impaired phenylalanine hydroxylase activity; defects of tetrahydrobiopterin metabolism can also cause hyperphenylalaninemia. Treatment follows mechanism: control phenylalanine exposure, ensure nutritional adequacy, and consider cofactor-responsive or enzyme-based approaches in appropriate patients.
- Maple syrup urine disease: impaired branched-chain α-ketoacid dehydrogenase blocks oxidative decarboxylation after branched-chain amino acid transamination. This is another TPP/lipoamide/FAD-dependent multienzyme system. Leucine accumulation is particularly important in neurotoxicity.
- Hyperammonemia: urea-cycle defects can produce severe neurological disease. Enzyme location predicts associated metabolites: for example, ornithine transcarbamylase deficiency can divert excess mitochondrial carbamoyl phosphate toward pyrimidine synthesis, increasing urinary orotic acid.
Historical connection: Krebs and Henseleit described the urea cycle in 1932, before Krebs and Johnson’s 1937 account of the citric acid cycle. The conceptual breakthrough was recognizing that a small regenerated pool of intermediates can support sustained transformation of a much larger substrate supply. [1,2]
12. Nucleotide Synthesis: Building Rings Versus Recycling Them
Purines are assembled on ribose; pyrimidine rings are assembled before attachment to ribose. This distinction organizes pathways that otherwise seem like disconnected lists.
- Purines: ribose 5-phosphate is activated to PRPP. Glutamine supplies the first committed nitrogen, and glycine, glutamine, aspartate, CO2, and formyl-tetrahydrofolate donate atoms as the ring is built toward IMP. IMP branches to AMP and GMP; AMP synthesis uses GTP, while GMP synthesis uses ATP, helping balance nucleotide pools.
- Pyrimidines: cytosolic CPS II supplies carbamoyl phosphate using glutamine nitrogen. Addition of aspartate, ring closure, and oxidation form orotate, which receives ribose phosphate from PRPP. Decarboxylation yields UMP. In humans, dihydroorotate dehydrogenase is associated with the inner mitochondrial membrane and transfers electrons to Q.
- Deoxyribonucleotides: ribonucleotide reductase uses radical chemistry to reduce ribonucleotide diphosphates. Thioredoxin or glutaredoxin systems connect its reducing requirement ultimately to NADPH.
- dTMP: thymidylate synthase converts dUMP to dTMP using methylene-tetrahydrofolate, producing dihydrofolate. Dihydrofolate reductase restores the reduced folate pool.
- Salvage: enzymes such as HGPRT reuse bases with PRPP, avoiding much of the energetic expense of de novo synthesis.
Pharmaceutical applications: fluorouracil’s metabolite FdUMP inhibits thymidylate synthase through a stable inhibitory complex; methotrexate inhibits dihydrofolate reductase; hydroxyurea interferes with ribonucleotide reductase radical chemistry. These drugs attack biosynthetic demands of proliferation, but proliferating normal tissues are also vulnerable. HGPRT deficiency in Lesch–Nyhan syndrome shows that salvage pathways are not optional housekeeping. [1,2]
13. Integration and the Peptide/Pharma Industry
Fed versus fasted metabolism is a coordinated change in priorities, not a global “on/off” switch. Insulin favors nutrient storage and growth through receptor tyrosine kinase signaling, PI3K–Akt pathways, enzyme regulation, and gene expression. Glucagon acts largely through hepatic cAMP–PKA signaling to maintain circulating fuels. AMPK responds to energetic stress through nucleotide-sensitive regulation and activating phosphorylation, suppressing costly anabolic processes while supporting ATP restoration.
Adenylate kinase: 2 ADP ⇌ ATP + AMP Energy charge: ([ATP] + 0.5[ADP]) / ([ATP] + [ADP] + [AMP]) Range: 0 = entirely AMP 1 = entirely ATP AMP can change proportionally much more than ATP, making it a sensitive indicator of energetic stress.
Type 1 diabetes illustrates the consequences of severe insulin deficiency: hepatic glucose production, adipose lipolysis, and ketogenesis can remain high despite abundant circulating glucose. Type 2 diabetes and metabolic syndrome involve tissue-specific insulin resistance and additional defects; they should not be reduced to a single broken enzyme.
Connections especially relevant to peptide therapeutics and manufacturing:
- GLP-1 receptor agonists: peptide medicines such as liraglutide and semaglutide alter an endocrine control system rather than directly inhibiting one metabolic enzyme. Their actions include glucose-dependent enhancement of insulin secretion, effects on glucagon secretion, appetite, and gastric emptying. Sequence modification and fatty-acid conjugation can improve resistance to degradation and extend exposure through albumin association. The lipid is chiefly a pharmacokinetic design element, not fuel delivery. [7]
- Insulin products: changing amino acid sequence, formulation, self-association, or albumin interactions changes absorption and duration. Pharmacokinetics determines whether a chemically active hormone reaches tissues with an appropriate time profile.
- Recombinant peptide production: microbial and mammalian hosts need carbon, nitrogen, ATP, and reducing power. Excess carbon supply can favor overflow metabolism, including acetate or lactate accumulation, rather than greater product yield. Feed design must account for oxygen transfer and metabolic capacity.
- Enzymatic synthesis: ATP-dependent ligases and NAD(P)H-dependent biocatalysts may require cofactor-regeneration systems. Economic process design depends on turnover, byproducts, mass balance, and energy regeneration—not only enzyme specificity.
- Nonribosomal peptide synthesis: adenylation domains activate amino acids using ATP → AMP + PPi; carrier-protein thiols hold intermediates as thioesters, and condensation domains build peptide bonds. This reuses the activated-acyl and swinging-arm logic encountered in fatty acid synthase and PDH.
14. Experimental Techniques: Asking What the Pathway Is Actually Doing
A. Coupled spectrophotometric enzyme assays. NADH absorbs strongly at 340 nm, whereas NAD+ absorbs weakly there. A reaction without a convenient optical signal can be coupled to NADH formation or consumption.
Example: pyruvate kinase assay PEP + ADP → pyruvate + ATP Pyruvate + NADH + H+ → lactate + NAD+ If coupling enzyme is in excess: Rate of NADH disappearance reports pyruvate kinase rate. Beer–Lambert law: A = εlc For NADH at 340 nm: ε ≈ 6.22 mM−1 cm−1 If ΔA340/Δt = −0.0622 min−1 and l = 1.00 cm: dc/dt = −0.0100 mM min−1 = −10.0 μM min−1 In 1.00 mL: Rate = 0.0100 μmol min−1 = 0.0100 enzyme units
Controls must establish that the coupling reaction is not limiting, background NADH oxidation is negligible, and the initial rate is linear. Microplate path lengths are not automatically 1 cm. A changing absorbance is evidence of chemistry, but assigning it to the intended enzyme requires controls.
B. Respirometry and extracellular flux analysis. Oxygen electrodes or optical sensors measure oxygen consumption. In intact-cell mitochondrial stress tests:
- Measure basal respiration.
- Add oligomycin: the decrease estimates ATP-synthesis-linked respiration under the assay conditions.
- Add a carefully titrated uncoupler such as FCCP: respiration can rise toward the system’s maximal electron-transfer and substrate-supply capacity.
- Add rotenone and antimycin A: residual oxygen consumption provides an operational estimate of nonmitochondrial respiration.
Reserve capacity is often estimated from maximal minus basal mitochondrial respiration. Extracellular acidification is not a pure lactate measurement because respiratory CO2 hydration also contributes. Cell number, viability, substrate supply, and drug dose must be controlled before interpreting differences as intrinsic mitochondrial defects.
C. Stable-isotope tracing and LC–MS. Feed a labeled substrate, quench metabolism rapidly, extract metabolites, and measure isotopologue distributions. For example, [U-13C6]glucose produces M+3 pyruvate. PDH generates M+2 acetyl-CoA, which initially forms M+2 citrate if it condenses with unlabeled oxaloacetate. Pyruvate carboxylase can instead form M+3 oxaloacetate when bicarbonate is unlabeled.
Here “M+n” means n additional mass units from heavy-isotope incorporation. Natural-abundance correction, tracer enrichment, compartmentation, reversible exchange, and labeling time matter. Labeling patterns constrain flux; they do not automatically equal flux. Dynamic or steady-state flux inference requires an explicit network model and appropriate uptake and secretion measurements. [6]
D. Metabolomics and energy/redox measurements. LC–MS and NMR can quantify or profile metabolites, while luciferase assays report ATP through ATP-dependent light production. Sample quenching is crucial because ATP, redox ratios, and intermediates can change within seconds. Pooling an entire cell also hides compartment-specific NADH/NAD+ ratios. A large metabolite pool can indicate high production, low consumption, or both.
E. Pulse–chase and perturbation experiments. A brief isotope pulse followed by unlabeled substrate reveals turnover and precursor–product relationships. Genetic deletion, acute inhibition, or enzyme replacement can test causality. Strong evidence combines orthogonal perturbations, rescue experiments, and direct product measurement; growth inhibition by itself does not identify a drug’s metabolic target.
15. Quantitative Reasoning: Concentration Is Not Flux
Skipper’s linear algebra now becomes a practical tool. Represent each reaction as a column of a stoichiometric matrix and each metabolite as a row.
Metabolite dynamics: dx/dt = S v x = vector of metabolite amounts or concentrations S = stoichiometric matrix v = vector of reaction rates At metabolic steady state: S v = 0 Steady state does not require v = 0. Inputs and outputs can balance while flux remains large.
A bathtub with equal inflow and outflow has a constant water level, but its turnover may be rapid. Likewise, unchanged citrate concentration does not imply unchanged TCA-cycle flux. Concentration measurements alone rarely identify all fluxes because several flux vectors can satisfy the same steady-state balance.
Michaelis–Menten model: v = Vmax[S] / (Km + [S]) Vmax = kcat[E]total Competitive inhibition: v = Vmax[S] / (αKm + [S]) α = 1 + [I]/Ki Flux control coefficient: CJ(E) = ∂ln J / ∂ln E
Michaelis–Menten kinetics is an important model, not a universal description of allosteric enzymes. Likewise, Km is not generally identical to a binding dissociation constant, and an inhibitor’s IC50 is not automatically its Ki. Substrate concentration and assay conditions affect potency estimates.
The “rate-limiting enzyme” is often a useful shortcut but a poor universal law. Flux control can be distributed among transporters, enzymes, cofactor supply, and product removal, and it can shift with physiological conditions. Increasing one enzyme’s abundance may barely change pathway output if control lies elsewhere.
Under conventional assumptions, complete aerobic oxidation of glucose gives roughly 30–32 ATP: 4 substrate-level ATP equivalents, 8 mitochondrial NADH from PDH and the TCA cycle, 2 Complex-II-linked electron pairs, and 2 cytosolic NADH whose contribution depends on the shuttle used. This estimate is a reconciliation of electron entry and transport costs—not a fixed cellular payout for every glucose molecule. [1,2]
16. Historical Synthesis: Why the Discoveries Changed the Questions
- Glycolysis and fermentation: work associated with Embden, Meyerhof, Parnas, and many others established that sugar breakdown could be dissected into enzyme-catalyzed reactions. Buchner’s earlier cell-free fermentation experiments helped show that such chemistry did not require an intact living cell.
- The Coris: Carl and Gerty Cori helped explain glycogen metabolism, glucose 1-phosphate, and interorgan cycling of carbohydrate carbon. Regulation became inseparable from tissue physiology.
- Krebs and collaborators: cyclic pathways showed how regenerated intermediates could organize sustained metabolism. The pathway diagram became a mass-balance model rather than a simple chain.
- Mitchell, Boyer, Walker, and single-molecule researchers: oxidative phosphorylation became understandable as a membrane-based electrochemical process coupled to a molecular rotary machine. Chemistry, electricity, and mechanics became one explanation. [3–5]
- Modern isotope tracing: pathway maps became testable quantitative models inside living systems. The central question shifted from “Is this enzyme present?” to “How much material actually moves through this route under these conditions?” [6]
My final checkpoint: I understand a pathway when I can predict what changes after an enzyme is inhibited, distinguish accumulated substrates from reduced flux, explain the ATP and electron balance, identify the relevant tissue and compartment, and propose an experiment that could prove my explanation wrong. Memorizing arrows is preparation for that task, not its completion.
Sources and Further Reading
- Nelson, D. L., and Cox, M. M. Lehninger Principles of Biochemistry. 8th ed. W. H. Freeman, 2021. Principal source for reaction mechanisms, pathway stoichiometry, bioenergetics, and integrated mammalian metabolism.
- Berg, J. M., Tymoczko, J. L., Gatto, G. J., Jr., and Stryer, L. Biochemistry. 9th ed. W. H. Freeman, 2019. Complementary treatment of enzyme mechanisms, metabolic regulation, and biochemical disease connections.
- Mitchell, P. “Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism.” Nature 191, 144–148 (1961). doi:10.1038/191144a0.
- Boyer, P. D. “The ATP Synthase—A Splendid Molecular Machine.” Annual Review of Biochemistry 66, 717–749 (1997). doi:10.1146/annurev.biochem.66.1.717. This is the published title associated with the DOI listed in the course materials.
- Noji, H., Yasuda, R., Yoshida, M., and Kinosita, K., Jr. “Direct observation of the rotation of F1-ATPase.” Nature 386, 299–302 (1997). doi:10.1038/386299a0.
- Jang, C., Chen, L., and Rabinowitz, J. D. “Metabolomics and Isotope Tracing.” Cell 173, 822–837 (2018). doi:10.1016/j.cell.2018.03.055.
- Knudsen, L. B., and Lau, J. “The Discovery and Development of Liraglutide and Semaglutide.” Frontiers in Endocrinology 10, 155 (2019). doi:10.3389/fendo.2019.00155.
- Brown, M. S., and Goldstein, J. L. “A receptor-mediated pathway for cholesterol homeostasis.” Science 232, 34–47 (1986). doi:10.1126/science.3513311.
🪬 Skipper's Reflection
1. What Surprised Me Most About This Material
Going into Biochemistry II, I expected a tedious ledger of carbon counting—memorizing metabolic flowcharts, enzyme names, and cofactors. What surprised me most was discovering that metabolism isn't just chemical plumbing; it is elegant, nanoscale mechanical engineering and complex network theory combined.
The absolute pinnacle of this surprise was studying ATP Synthase. Reading Paul Boyer’s 1997 paper, "The Rotary Mechanism of ATP Synthase", completely shattered my preconceived notions of how enzymes work. I had visualized enzymes as static locks and keys, occasionally undergoing conformational shifts. But the F₁F₀ ATP synthase is a literal, physical rotary motor. The flow of protons down the electrochemical gradient physically spins the c-ring in the membrane, rotating the $\gamma$ shaft, which forces the $\beta$ subunits of the F₁ head through three distinct mechanical states (Open, Loose, Tight). It physically crushes ADP and Pi together to make ATP. Seeing thermodynamics (the proton-motive force) translated into pure Newtonian rotational mechanics at the molecular level was staggering.
2. The Conceptual Breakthrough Moments — When Things Clicked
My first major "aha" moment was understanding the true nature of ATP. In earlier biology classes, ATP was lazily called an "energy battery." But looking at it through the lens of Lehninger and physical chemistry, it clicked: ATP is valuable precisely because it is thermodynamically unstable but kinetically stable. It has a high phosphoryl group transfer potential, but without an enzyme, it won't just spontaneously hydrolyze in water. This allows the cell to perfectly control and couple its highly exergonic hydrolysis to drive endergonic reactions.
The second breakthrough was realizing that metabolic pathways aren't just one-way streets—they are traffic circles. The TCA cycle isn't merely a furnace for burning acetyl-CoA; it’s a central hub. When I learned about anaplerotic (replenishing) reactions, I finally understood why amino acid catabolism and gluconeogenesis are so deeply intertwined. If you pull $\alpha$-ketoglutarate out to make glutamate, the cycle would stall if not for pyruvate carboxylase refilling oxaloacetate.
Finally, the logic of regulation clicked when studying Phosphofructokinase-1 (PFK-1) and Fructose 2,6-bisphosphate. The fact that a tiny side-product (F2,6BP) acts as an allosteric volume dial to prevent glycolysis and gluconeogenesis from running simultaneously (a futile substrate cycle) was a beautiful example of evolutionary logic. It isn't just about turning enzymes on or off; it's about shifting their $K_m$ to tune pathway flux to the exact energy state of the cell.
3. How This Changes How I Think About Peptides
This course completely transformed my understanding of the metabolic peptides we work with, shifting them in my mind from "weight loss drugs" to profound molecular regulators of the exact pathways I just studied.
Take Tirzepatide and Retatrutide. In class, we learned that insulin (fed state) and glucagon (fasted state) are essentially opposing forces. Insulin promotes glycolysis, glycogen synthesis, and fatty acid biosynthesis. Glucagon promotes gluconeogenesis, glycogenolysis, and fatty acid oxidation (via cAMP cascades activating Protein Kinase A). Retatrutide is a triple agonist (GLP-1, GIP, and Glucagon). From a classical biochemical standpoint, agonizing both insulin-stimulating (GLP-1/GIP) and glucagon receptors simultaneously seems contradictory. But looking at the metabolic integration maps, it makes brilliant sense: the glucagon agonism forces the liver into hyper-drive, increasing fatty acid $\beta$-oxidation and energy expenditure, while the GLP-1/GIP components manage glucose clearance and brain satiety. We are literally hacking the liver's AMPK and cAMP energy-sensing networks to force a negative energy balance without triggering the body's starvation panic.
For regenerative peptides like BPC-157 and TB-500, tissue healing requires massive cellular proliferation. Thanks to this course, I now realize this means these peptides must indirectly stimulate the Pentose Phosphate Pathway (PPP) to generate ribose-5-phosphate for DNA/RNA synthesis, and massive amounts of NADPH to fuel the lipid biosynthesis required for new cell membranes. Healing isn't just "growth"—it is a highly orchestrated, localized metabolic massive-scaling event.
4. Questions This Course Raises That I Want to Investigate Further
The regulation of these pathways raises some fascinating questions about the limits of human biochemistry:
- Kinetic Flux vs. Steady State: We modeled metabolic integration mostly in steady states (fed vs. fasted). But what are the transition kinetics? When AMPK is suddenly activated, how long does the physical wave of phosphorylation take to propagate through a hepatocyte and shift the flux from fatty acid synthesis to $\beta$-oxidation?
- Peptide-Induced Futile Cycling: If poly-agonists like Retatrutide hit competing receptors, do they induce futile substrate cycles (like simultaneously running glycolysis and gluconeogenesis)? Could the heat generated by such futile cycling actually be a mechanism of the increased metabolic rate and weight loss?
- Allosteric vs. Covalent Modification Speed: I want to dig deeper into the mathematical modeling of how fast allosteric regulation (like AMP binding PFK-1) acts compared to covalent modification (like phosphorylation of glycogen phosphorylase).
5. Rating My Confidence Level
Topics I feel most confident about:
- Bioenergetics and ATP Synthase: Thanks to Boyer's paper and my background in thermodynamics from Physical Chemistry, the rotary mechanics and P/O ratios make perfect logical sense.
- Glycolysis and the TCA Cycle: Tracing the carbons and understanding the mechanistic chemistry (like the TPP and Lipoic Acid swinging arms in the Pyruvate Dehydrogenase complex) feels very intuitive.
- Metabolic Integration: The hormonal control via insulin, glucagon, and AMPK maps beautifully to the systemic logic I learned in Human Physiology.
Topics I feel least confident about (Need more review):
- Nucleotide Biosynthesis: The sheer number of steps in the de novo purine and pyrimidine synthesis pathways feels somewhat arbitrary to me right now. I need to spend more time finding the underlying chemical logic rather than just brute-force memorizing the PRPP additions.
- Cholesterol Biosynthesis: The early steps (HMG-CoA to mevalonate) are clear, but visualizing the exact condensation reactions of the isoprenoids (farnesyl pyrophosphate folding to squalene) is still difficult for me. I need to review the 3D stereochemistry of these transitions.
🗺️ Visual Aids & Key Takeaways
Diagram 1: The Ten Enzymes of Glycolysis — Substrates, Products, and Regulatory Nodes
╔══════════════════════════════════════════════════════════════════════════════════════════╗
║ GLYCOLYSIS: FROM GLUCOSE TO PYRUVATE ║
║ cytoplasm · net yield: 2 ATP, 2 NADH, 2 pyruvate ║
╚══════════════════════════════════════════════════════════════════════════════════════════╝
GLUCOSE (6C)
│
│ ① HEXOKINASE (or glucokinase in liver)
│ ATP → ADP · inhibited by G6P (hexokinase only)
↓ [REGULATION NODE ◆]
GLUCOSE-6-PHOSPHATE (6C)
│
│ ② PHOSPHOGLUCOSE ISOMERASE
│ aldose ⇌ ketose
↓
FRUCTOSE-6-PHOSPHATE (6C)
│
│ ③ PHOSPHOFRUCTOKINASE-1 (PFK-1)
│ ATP → ADP
│ [MAJOR REGULATION NODE ◆◆◆]
│ (+) AMP, ADP, F-2,6-BP, insulin (via F-2,6-BP)
│ (−) ATP, citrate, glucagon (via ↓F-2,6-BP)
↓
FRUCTOSE-1,6-BISPHOSPHATE (6C)
│
│ ④ ALDOLASE
│ cleaves C–C bond (class I: Schiff base mechanism)
↓ ↓
DHAP (3C) GLYCERALDEHYDE-3-PHOSPHATE (G3P, 3C)
│ │
└──⑤ TPI ───────┘ (triose phosphate isomerase)
│ DHAP ⇌ G3P (rapid equilibrium)
│
│ ⑥ GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE
│ NAD⁺ → NADH · Pi incorporated
↓
1,3-BISPHOSPHOGLYCERATE (3C)
│
│ ⑦ PHOSPHOGLYCERATE KINASE
│ ADP → ATP (substrate-level phosphorylation #1)
↓
3-PHOSPHOGLYCERATE (3C)
│
│ ⑧ PHOSPHOGLYCERATE MUTASE
│ shifts phosphate: C3 → C2
↓
2-PHOSPHOGLYCERATE (3C)
│
│ ⑨ ENOLASE
│ eliminates H₂O → high-energy enol phosphate
│ inhibited by F (fluoride, not a physiological regulator)
↓
PHOSPHOENOLPYRUVATE (PEP, 3C)
│
│ ⑩ PYRUVATE KINASE
│ ADP → ATP (substrate-level phosphorylation #2)
│ [REGULATION NODE ◆◆]
│ (+) F-1,6-BP (feedforward activation)
│ (−) ATP, alanine, glucagon (phosphorylation inactivates)
↓
PYRUVATE (3C)
│
┌────┴─────────────────────────────┐
↓ ↓
aerobic: PDH complex anaerobic: lactate
→ Acetyl-CoA → TCA dehydrogenase
NADH re-oxidized
All ten glycolytic enzymes in sequence, showing carbon counts, cofactor changes, and the three physiologically regulated steps (hexokinase, PFK-1, pyruvate kinase) that prevent glycolysis from running as a futile cycle with gluconeogenesis.
---Diagram 2: The TCA Cycle — All Eight Enzymes, Cofactors, and Outputs
╔══════════════════════════════════════════════════════════════════════════════════════════╗
║ THE TCA CYCLE (KREBS CYCLE / CITRIC ACID CYCLE) ║
║ mitochondrial matrix · per acetyl-CoA turn: 3 NADH, 1 FADH₂, 1 GTP, 2 CO₂ ║
╚══════════════════════════════════════════════════════════════════════════════════════════╝
ACETYL-CoA (2C)
│
│ + OXALOACETATE (4C)
↓
┌─────────────────────┐
│ ① CITRATE │ 4C + 2C → 6C
│ SYNTHASE │ CoA released; highly exergonic
└─────────────────────┘
│
CITRATE (6C)
│
┌─────────────────────┐
│ ② ACONITASE │ dehydration then rehydration
│ │ Fe–S cluster active site
└─────────────────────┘
│
ISOCITRATE (6C)
│
┌─────────────────────┐
│ ③ ISOCITRATE │ [REGULATION NODE ◆◆]
│ DEHYDROGENASE │ NAD⁺ → NADH · CO₂ lost
│ │ (+) ADP, Ca²⁺
└─────────────────────┘ (−) ATP, NADH
│
α-KETOGLUTARATE (5C)
│
┌─────────────────────┐
│ ④ α-KG │ [REGULATION NODE ◆◆]
│ DEHYDROGENASE │ NAD⁺ → NADH · CO₂ lost · CoA added
│ COMPLEX │ structurally analogous to PDH complex
└─────────────────────┘ (−) succinyl-CoA, NADH
│
SUCCINYL-CoA (4C) ← anaplerosis entry point
│ (odd-chain FA, Val, Ile, Met)
┌─────────────────────┐
│ ⑤ SUCCINYL-CoA │ substrate-level phosphorylation
│ SYNTHETASE │ GDP + Pi → GTP (or ADP → ATP in some tissues)
└─────────────────────┘
│
SUCCINATE (4C)
│
┌─────────────────────┐
│ ⑥ SUCCINATE │ FAD → FADH₂ (enzyme-bound)
│ DEHYDROGENASE │ this IS Complex II of ETC
└─────────────────────┘ (−) malonate (competitive inhibitor)
│
FUMARATE (4C)
│
┌─────────────────────┐
│ ⑦ FUMARASE │ trans-addition of H₂O
│ (FUMARATE │ stereospecific: yields L-malate only
│ HYDRATASE) │
└─────────────────────┘
│
L-MALATE (4C)
│
┌─────────────────────┐
│ ⑧ MALATE │ NAD⁺ → NADH
│ DEHYDROGENASE │ equilibrium favors malate,
└─────────────────────┘ pulled forward by citrate synthase
│
OXALOACETATE (4C) ──── regenerated; accepts next acetyl-CoA
also: gluconeogenesis, amino acid synthesis
ANAPLEROTIC ENTRY POINTS (replenish cycle intermediates):
─────────────────────────────────────────────────────────
Pyruvate ──[pyruvate carboxylase]──→ OXALOACETATE
Glutamate ──[transamination/GDH]────→ α-KETOGLUTARATE
Aspartate ──[transamination]────────→ OXALOACETATE
Propionyl-CoA ─[3 steps]────────────→ SUCCINYL-CoA
The complete TCA cycle showing all eight enzymes, points of CO₂ release and cofactor reduction, substrate-level phosphorylation, and the anaplerotic reactions that replenish cycle intermediates depleted by biosynthetic demands.
---Diagram 3: The Mitochondrial Electron Transport Chain and ATP Synthase
╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║ ELECTRON TRANSPORT CHAIN + ATP SYNTHASE (oxidative phosphorylation) ║
║ inner mitochondrial membrane · intermembrane space (IMS) above, matrix below ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝
IMS (high H⁺, + charge)
─────────────────────────────────────────────────────────────────────────────────────────────
↑ 4H⁺ ↑ 4H⁺ ↑ 2H⁺ ↑ 4H⁺ ║ ← H⁺ flows down
│ │ │ │ ║ electrochemical
│ │ │ │ ║ gradient
┌──────┐ ┌──────┐ ┌──────┐ ┌──────┐ ║
│ │ │ │ │ │ │ │ ║ F₀ subunit
│ I │ │ II │ CoQ │ III │ Cyt c │ IV │ ║ (membrane rotor)
│NADH │ │FADH₂ │ ~~~~~~→ │ bc₁ │ ·~·~·~·~→ │ COX │ ║
│dehy- │ │succ. │ │ │ │ │ ║ F₁ subunit
│drog. │ │dehy- │ │ │ │ │ ║ (matrix catalytic
│ │ │drog. │ │ │ │ │ ½O₂+2H⁺ ║ head)
└──────┘ └──────┘ └──────┘ └──────┘ →H₂O ║
│ │ ║
NADH→NAD⁺ FADH₂→FAD ║ ~2.7 H⁺ per ATP
(−0.32V) (+0.03V) O₂ (+0.82V) ║ (3 sites × ~3 H⁺)
─────────────────────────────────────────────────────────────────────────────────────────────
MATRIX (low H⁺, − charge)
COMPLEXES AT A GLANCE:
┌──────────────────────────────────────────────────────────────────────────────┐
│ COMPLEX │ SUBUNITS │ PROSTHETIC GROUPS │ PROTONS PUMPED │ E° (donor) │
├──────────┼──────────┼───────────────────────┼────────────────┼──────────────┤
│ I │ ~45 │ FMN, 8 Fe-S clusters │ 4 H⁺ │ NADH │
│ II │ 4 │ FAD, Fe-S, heme b │ 0 H⁺ │ FADH₂ │
│ III │ 11 │ heme b_L, b_H, c₁, Fe-S│ 4 H⁺ │ CoQH₂ │
│ IV │ 13 │ Cu_A, heme a, a₃, Cu_B │ 2 H⁺* │ Cyt c │
└──────────┴──────────┴───────────────────────┴────────────────┴──────────────┘
* Complex IV translocates 2 H⁺ and consumes 2 H⁺ from matrix to reduce O₂
ATP SYNTHASE (Complex V) — THE ROTARY MOTOR:
┌─────────────────────────────────────────────────────────────────┐
│ │
│ INTERMEMBRANE SPACE │
│ H⁺ →→→ enters through F₀ a-subunit half-channel │
│ ↓ │
│ ┌──────────────────────────────────┐ │
│ │ F₀ (membrane) │ c-ring (10–15 subunits) │
│ │ H⁺ binds Asp on c-ring │ rotates as H⁺ flows │
│ └──────────────────────────────────┘ │
│ ↓ rotation transmitted via γ-subunit │
│ ┌──────────────────────────────────┐ │
│ │ F₁ (matrix) │ α₃β₃ hexamer, fixed │
│ │ 3 catalytic β-subunits │ γ rotates inside them │
│ │ Boyer's binding-change mechanism│ │
│ │ OPEN → LOOSE → TIGHT → OPEN │ │
│ └──────────────────────────────────┘ │
│ ADP + Pi →[TIGHT]→ ATP →[OPEN]→ ATP released │
└─────────────────────────────────────────────────────────────────┘
P/O RATIOS (modern consensus):
NADH → ~2.5 ATP per pair of electrons
FADH₂ → ~1.5 ATP per pair of electrons
(older textbook values of 3 and 2 are now considered overestimates)
The mitochondrial inner membrane showing all four electron transport complexes with their electron donors, proton pumping stoichiometries, and prosthetic groups, plus the F₁F₀ ATP synthase rotary mechanism that converts the proton-motive force into ATP.
---Diagram 4: Central Metabolic Integration — Fed vs. Fasted State Hormone Signaling
╔══════════════════════════════════════════════════════════════════════════════════════════╗
║ METABOLIC INTEGRATION: FED vs. FASTED ║
╚══════════════════════════════════════════════════════════════════════════════════════════╝
FED STATE (↑ glucose, ↑ INSULIN) FASTED STATE (↓ glucose, ↑ GLUCAGON)
────────────────────────────────── ─────────────────────────────────────
β-cells secrete INSULIN α-cells secrete GLUCAGON
│ │
│ binds RTK on: │ binds GPCR on:
├─ LIVER ├─ MUSCLE ├─ FAT ├─ LIVER ├─ FAT
│ │
↓ ↓
┌───────────────────────────┐ ┌───────────────────────────────────┐
│ INSULIN EFFECTS │ │ GLUCAGON EFFECTS │
│ │ │ │
│ Liver: │ │ Liver: │
│ ↑ glycolysis (↑PFK-1 │ │ ↑ gluconeogenesis │
│ via ↑F-2,6-BP) │ │ ↑ glycogenolysis │
│ ↑ glycogen synthesis │ │ ↓ glycolysis (↓F-2,6-BP │
│ ↑ fatty acid synthesis │ │ via PKA phosphorylates │
│ ↓ gluconeogenesis │ │ PFK-2/FBPase-2) │
│ ↓ ketogenesis │ │ ↑ fatty acid oxidation │
│ │ │ ↑ ketogenesis │
│ Muscle: │ │ │
│ ↑ GLUT4 to membrane │ │ Adipose: │
│ ↑ glycogen synthesis │ │ ↑ lipolysis (hormone- │
│ ↑ protein synthesis │ │ sensitive lipase active) │
│ │ │ ↑ free FA release to blood │
│ Adipose: │ │ │
│ ↑ glucose uptake │ │ │
│ ↑ triglyceride storage │ │ │
│ ↓ lipolysis │ │ │
└───────────────────────────┘ └───────────────────────────────────┘
AMPK: THE CELLULAR ENERGY SENSOR (acts in BOTH states when ATP falls)
──────────────────────────────────────────────────────────────────────
↑ AMP:ATP ratio → AMPK activated (phosphorylated by LKB1)
│
│ phosphorylates:
├──→ ACC (acetyl-CoA carboxylase) INACTIVATED → ↓malonyl-CoA
│ → carnitine shuttle opens → ↑ β-oxidation
├──→ HMG-CoA reductase INACTIVATED → ↓ cholesterol synthesis
├──→ GLYCOGEN SYNTHASE INACTIVATED → ↓ glycogen storage
└──→ transcription factors → ↑ mitochondrial biogenesis
KEY BIFUNCTIONAL ENZYME:
PFK-2 / FBPase-2
──────────────────
Dephosphorylated (insulin) → PFK-2 active → ↑ F-2,6-BP → ↑ PFK-1 → glycolysis ON
Phosphorylated (glucagon) → FBPase-2 active → ↓ F-2,6-BP → ↓ PFK-1 → glycolysis OFF
The opposing actions of insulin and glucagon on key metabolic pathways in liver, muscle, and adipose tissue, with AMPK as the energy-sensing integrator that responds to the AMP:ATP ratio regardless of hormonal status.
---Diagram 5: β-Oxidation of Fatty Acids and Entry into Ketogenesis
╔══════════════════════════════════════════════════════════════════════════════════════════╗
║ FATTY ACID β-OXIDATION (mitochondrial matrix) ║
║ example: palmitoyl-CoA (16C) → 8 acetyl-CoA per full degradation ║
╚══════════════════════════════════════════════════════════════════════════════════════════╝
ACTIVATION (cytoplasm / outer mitochondrial membrane):
─────────────────────────────────────────────────────
Fatty acid + CoA + ATP ──[acyl-CoA synthetase]──→ Fatty acyl-CoA + AMP + PPi
(PPi → 2Pi, pulls reaction forward)
CARNITINE SHUTTLE (inner mitochondrial membrane):
──────────────────────────────────────────────────
Fatty acyl-CoA ──[CPT-I]──→ Acylcarnitine →→ translocase →→ Acylcarnitine (matrix)
(cytoplasm) │
CPT-I inhibited by malonyl-CoA (prevents futile cycle with biosynthesis) │
[CPT-II] ──→ Fatty acyl-CoA
(matrix, regenerated)
β-OXIDATION CYCLE (4 steps, repeated):
────────────────────────────────────────
┌──────────────────────────────────────────────────────────────────────────────┐
│ │
│ Fatty acyl-CoA (2n carbons) │
│ │ │
│ ① ACYL-CoA DEHYDROGENASE │
│ FAD → FADH₂ (electrons → ETF → Complex II/CoQ) │
│ introduces trans Δ² double bond │
│ │ │
│ trans-Δ²-Enoyl-CoA │
│ │ │
│ ② ENOYL-CoA HYDRATASE │
│ H₂O added across double bond │
│ stereospecific: yields L-3-hydroxyacyl-CoA │
│ │ │
│ L-3-Hydroxyacyl-CoA │
│ │ │
│ ③ 3-HYDROXYACYL-CoA DEHYDROGENASE │
│ NAD⁺ → NADH │
│ oxidizes hydroxyl to ketone │
│ │ │
│ 3-Ketoacyl-CoA │
│ │ │
│ ④ β-KETOTHIOLASE (THIOLASE) │
│ CoA-SH attacks; C–C bond cleaved │
│ releases: ACETYL-CoA + Fatty acyl-CoA (shortened by 2C) │
│ │ │ │
│ ↓ └── BACK TO TOP of cycle ──┐ │
│ → TCA cycle │ │
└──────────────────────────────────────────────────────────────────────────────┘
YIELD FROM PALMITOYL-CoA (16C):
─────────────────────────────────
7 cycles of β-oxidation → 7 FADH₂ + 7 NADH + 8 Acetyl-CoA
8 Acetyl-CoA × 10 ATP eq. = 80 ATP eq.
7 FADH₂ × 1.5 ATP eq. = 10.5 ATP eq.
7 NADH × 2.5 ATP eq. = 17.5 ATP eq.
subtract activation cost = −2 ATP eq. (ATP → AMP + PPi)
────────────
net ≈ 106 ATP equivalents per palmitate
KETOGENESIS (liver mitochondria, during fasting/diabetes):
───────────────────────────────────────────────────────────
Acetyl-CoA accumulates when OAA is depleted (used for gluconeogenesis)
2 Acetyl-CoA → Acetoacetyl-CoA (thiolase, reverse)
Acetoacetyl-CoA + Acetyl-CoA → HMG-CoA [HMG-CoA synthase]
HMG-CoA → Acetoacetate + Acetyl-CoA [HMG-CoA lyase]
Acetoacetate → β-hydroxybutyrate (NADH) or acetone (spontaneous)
↓
Exported to blood → brain, heart use as fuel during starvation
(brain normally uses glucose; switches to ketones after ~3 days fast)
The complete pathway of fatty acid activation, mitochondrial import via the carnitine shuttle, the four-step β-oxidation cycle, the energetic yield from palmitate, and the overflow pathway to ketone body formation when acetyl-CoA exceeds TCA cycle capacity.
---Key Takeaways
- PFK-1 is the irreversible, rate-limiting commitment step of glycolysis. It is allosterically activated by AMP and fructose-2,6-bisphosphate (F-2,6-BP) — the most potent activator — and inhibited by ATP and citrate. F-2,6-BP is synthesized by the bifunctional enzyme PFK-2/FBPase-2, which is itself regulated by phosphorylation: insulin promotes dephosphorylation (PFK-2 active, F-2,6-BP rises, glycolysis on), while glucagon promotes phosphorylation (FBPase-2 active, F-2,6-BP falls, glycolysis off). This single regulatory metabolite explains how a cell can simultaneously sense nutrient status (AMP) and hormonal status (insulin/glucagon) at one enzyme.
- The pyruvate dehydrogenase complex (PDH) uses five cofactors in strict sequence: TPP, lipoic acid, CoA, FAD, and NAD⁺. Three enzymatic components (E1 pyruvate decarboxylase, E2 dihydrolipoyl transacetylase, E3 dihydrolipoyl dehydrogenase) pass the substrate hand-to-hand via the lipoic acid "swinging arm" covalently attached to E2. PDH is inactivated by phosphorylation (PDH kinase, activated by high acetyl-CoA, NADH, ATP) and reactivated by dephosphorylation (PDH phosphatase, activated by Ca²⁺ and insulin). This gate controls the irreversible commitment of pyruvate to oxidative metabolism and explains why the cell cannot synthesize glucose from acetyl-CoA — the reaction is thermodynamically and biochemically irreversible.
- Succinate dehydrogenase (Complex II) is the only TCA cycle enzyme embedded in the inner mitochondrial membrane and simultaneously a component of the ETC. It oxidizes succinate to fumarate using FAD as the electron acceptor, generating FADH₂ that directly reduces CoQ. Because Complex II does not pump protons, FADH₂-derived electrons enter the ETC "downstream" of the first proton-pumping step, yielding approximately 1.5 ATP rather than the 2.5 ATP produced per NADH. This mechanistic fact explains why fats (rich in fully reduced carbons, generating more FADH₂/NADH) yield more ATP per carbon than carbohydrates, but also why the two electron carriers have different energetic values.
- Boyer's rotary binding-change mechanism for ATP synthase: The three β-subunits of F₁ cycle through three conformations — Open (low affinity, releases ATP), Loose (binds ADP + Pi), and Tight (high affinity, synthesizes ATP without requiring energy input; the energy drives conformational change, not the chemical reaction itself). The γ-subunit rotates inside the α₃β₃ hexamer driven by proton flow through the c-ring of F₀, and each 120° rotation converts one β-subunit's conformation. Approximately 8–15 protons are required per full rotation (depending on c-ring size), yielding ~3 ATP per rotation, giving roughly 2.7 H⁺ per ATP (Nelson & Cox, 2021). The key insight is that ATP synthesis itself is energetically easy; it is ATP release from the enzyme that requires the proton-motive force.
- The modern P/O ratios are ~2.5 for NADH and ~1.5 for FADH₂ — not the textbook values of 3 and 2 that appeared in older editions. These revised values account for the actual H⁺/ATP stoichiometry of ATP synthase (~2.7 H⁺/ATP) and the energetic cost of transporting ADP, Pi, and ATP across the inner mitochondrial membrane via the ATP/ADP translocase and phosphate carrier (which consume ~1 H⁺ per ATP exported). A complete oxidation of glucose therefore yields approximately 30–32 ATP, not the often-cited 36–38 (Nelson & Cox, 2021).
- Malonyl-CoA is the master switch preventing simultaneous fatty acid synthesis and oxidation. When acetyl-CoA carboxylase (ACC) is active (fed state, dephosphorylated, stimulated by citrate), it produces malonyl-CoA, which potently inhibits CPT-I (carnitine palmitoyl transferase I), the enzyme that imports fatty acids into mitochondria for β-oxidation. AMPK phosphorylates and inactivates ACC, dropping malonyl-CoA levels and reopening the carnitine shuttle. This elegant reciprocal regulation ensures that when the cell is building fatty acids, it is not simultaneously burning them — a futile cycle that would waste ATP.
- Gluconeogenesis is not simply the reverse of glycolysis. Seven of the ten glycolytic steps are thermodynamically reversible and shared. Three irreversible glycolytic steps (hexokinase, PFK-1, pyruvate kinase) are bypassed by four dedicated gluconeogenic enzymes: (1) pyruvate carboxylase (pyruvate → OAA, requires biotin and ATP, mitochondrial), (2) PEPCK (OAA → PEP + CO₂, requires GTP, cytoplasmic), (3) fructose-1,6-bisphosphatase (F-1,6-BP → F-6-P, inhibited by AMP and F-2,6-BP), and (4) glucose-6-phosphatase (G6P → glucose, ER membrane, liver/kidney only). The energy cost is high: 6 ATP equivalents per glucose synthesized vs. 2 ATP gained per glucose degraded — reflecting thermodynamic irreversibility at each bypass.
- The urea cycle disposes of nitrogen as urea, requiring 4 ATP equivalents per cycle, and is regulated primarily at carbamoyl phosphate synthetase I (CPS-I). CPS-I in the mitochondrial matrix requires N-acetylglutamate (NAG) as an obligate allosteric activator. NAG synthesis is stimulated by arginine, creating a feedforward loop: when amino acid catabolism is high (arginine levels rise), NAG synthesis increases, CPS-I is activated, and urea cycle flux increases. The cycle spans two compartments: the first two steps occur in the mitochondria (carbamoyl phosphate + ornithine → citrulline), and the remaining steps in the cytoplasm. Fumarate is a byproduct that directly connects the urea cycle to the TCA cycle — an elegant metabolic link.
- The pentose phosphate pathway (PPP) serves two distinct purposes that can be uncoupled by the non-oxidative branch. The oxidative branch irreversibly produces 2 NADPH and 1 CO₂ per glucose-6-phosphate oxidized, generating ribose-5-phosphate for nucleotide synthesis. The non-oxidative branch (using transketolase and transaldolase, both requiring TPP) interconverts sugar phosphates reversibly, allowing: (a) excess ribose-5-P to be funneled back into glycolysis as F-6-P and G3P, or (b) fructose-6-P and G3P from glycolysis to be converted into ribose-5-P without producing NADPH. A cell can thus tune NADPH vs. ribose-5-P production independently according to need. G6PD deficiency (the most common human enzyme defect) impairs NADPH production, leading to hemolytic anemia upon oxidative stress because red blood cells cannot regenerate glutathione.
- The HMG-CoA reductase step is the committed, rate-limiting, and pharmacologically targeted step in cholesterol biosynthesis. HMG-CoA reductase (in the ER membrane) converts HMG-CoA to mevalonate using 2 NADPH, and is inhibited by statins (competitive inhibitors that mimic the transition state), by AMPK phosphorylation, by high cholesterol (which triggers INSIG-mediated HMGCR degradation via the SCAP/SREBP pathway), and by oxysterols. Each mole of cholesterol requires 18 acetyl-CoA, 16 NADPH, and 36 ATP equivalents — making it one of the most energetically expensive biosynthetic products in the cell. This cost is why tight regulation is essential.
- Pyridoxal phosphate (PLP) is the essential cofactor for virtually all transamination reactions and many other amino acid transformations (decarboxylation, racemization, elimination). In transamination, PLP forms a Schiff base (aldimine) with the amino group of the donor amino acid. Hydrolysis of the ketimine intermediate yields pyridoxamine phosphate (PMP) and the α-keto acid product. The aminotransferases ALT (alanine + α-KG ⇌ pyruvate + glutamate) and AST (aspartate + α-KG ⇌ OAA + glutamate) are diagnostically important — elevated serum ALT and AST indicate hepatocellular damage because these enzymes are normally intracellular. Glutamate is the central nitrogen-collecting hub: most amino groups are transferred to α-ketoglutarate to form glutamate before entering the urea cycle.
- Glycogen phosphorylase is activated by phosphorylation and by AMP (in muscle), and inactivated by dephosphorylation, ATP, and G6P. The cAMP cascade (glucagon/epinephrine → adenylyl cyclase → PKA → phosphorylase kinase → glycogen phosphorylase a) amplifies the hormonal signal ~10⁶-fold at each step. Glycogen phosphorylase cleaves glycogen by phosphorolysis — using inorganic phosphate rather than water — releasing glucose-1-phosphate directly, which is then converted to G6P for glycolysis without spending an ATP. This is the energetic advantage of storing glucose as glycogen rather than free glucose: mobilization is essentially free. Debranching requires a separate enzyme with two activities: a transferase and an α-1,6-glucosidase, the latter releasing free glucose (which does require phosphorylation before glycolysis).
- Branched-chain amino acid (BCAA) catabolism — leucine, isoleucine, valine — is initiated in muscle (not liver) because muscle expresses BCAA aminotransferase. After transamination to their α-keto acids, all three undergo oxidative decarboxylation by the branched-chain α-keto acid dehydrogenase complex (BCKDH), which is structurally homologous to PDH and α-KG dehydrogenase and uses the same five cofactors. BCKDH deficiency causes maple syrup urine disease (MSUD), so named for the characteristic odor of accumulated branched-chain keto acids in urine. Leucine is purely ketogenic (→ acetyl-CoA, acetoacetate); valine is purely glucogenic (→ succinyl-CoA); isoleucine is both. The differential tissue expression of BCAA aminotransferase explains why BCAA nitrogen is first exported as alanine and glutamine from muscle to liver before entering the urea cycle — a central feature of inter-organ nitrogen metabolism.
- De novo purine synthesis builds the ring directly on ribose-5-phosphate over 10 enzyme-catalyzed steps, beginning with PRPP. The first committed step is catalyzed by glutamine phosphoribosyl pyrophosphate amidotransferase (the "PRPP amidotransferase"), which transfers an amide nitrogen from glutamine to PRPP. The pathway is energetically costly (~6 ATP per IMP) and its first product is inosine monophosphate (IMP), from which both AMP and GMP are derived via divergent pathways. In contrast, pyrimidine synthesis builds the ring first (as orotic acid) and then attaches it to PRPP — the opposite strategy. PRPP is also the starting point for salvage pathways (HGPRT uses PRPP + hypoxanthine or guanine; APRT uses PRPP + adenine). HGPRT deficiency causes Lesch-Nyhan syndrome; its gout-like symptoms arise from overproduction of uric acid (the end product of purine catabolism in humans, due to loss of uricase during primate evolution).
References
- David L. Nelson and Michael M. Cox, Lehninger Principles of Biochemistry, 8th ed. (New York: W. H. Freeman/Macmillan Learning, 2021). ISBN: 978-1-319-22800-0.
- Jeremy M. Berg, John L. Tymoczko, Gregory J. Gatto Jr., and Lubert Stryer, Biochemistry, 9th ed. (New York: W. H. Freeman/Macmillan Learning, 2019). ISBN: 978-1-319-11467-1.
- Paul D. Boyer, 'The ATP Synthase — A Splendid Molecular Machine,' Annual Review of Biochemistry, vol. 66, 1997, pp. 717–749. DOI: 10.1146/annurev.biochem.66.1.717. (Nobel Lecture context; Boyer shared the 1997 Nobel Prize in Chemistry for elucidating the rotary catalytic mechanism.)
- John E. Walker, 'ATP Synthesis by Rotary Catalysis,' Annual Review of Biochemistry, vol. 67, 1998, pp. 29–50. DOI: 10.1146/annurev.biochem.67.1.29. (Complementary structural perspective from Walker, who shared the 1997 Nobel Prize.)
- David G. Nicholls and Stuart J. Ferguson, Bioenergetics 4 (Amsterdam: Academic Press/Elsevier, 2013). ISBN: 978-0-12-388425-1. (Authoritative treatment of proton-motive force, P/O ratios, and mitochondrial membrane transport.)
- D. Grahame Hardie, Fiona A. Ross, and Simon A. Hawley, 'AMPK: A Nutrient and Energy Sensor That Maintains Energy Homeostasis,' Nature Reviews Molecular Cell Biology, vol. 13, no. 4, 2012, pp. 251–262. DOI: 10.1038/nrm3311.
- Keith Frayn, Metabolic Regulation: A Human Perspective, 3rd ed. (Oxford: Wiley-Blackwell, 2010). ISBN: 978-1-405-18351-4. (Particularly useful for inter-organ metabolic integration, fed/fasted physiology, and clinical perspectives on diabetes and metabolic syndrome.)
- Emile Van Schaftingen and Isabelle Gerin, 'The Glucose-6-Phosphatase System,' Biochemical Journal, vol. 362, no. 3, 2002, pp. 513–532. DOI: 10.1042/bj3620513. (Detailed mechanism of the ER-localized glucose-6-phosphatase relevant to gluconeogenesis.)
- Peter A. Srere, 'Complexes of Sequential Metabolic Enzymes,' Annual Review of Biochemistry, vol. 56, 1987, pp. 89–124. DOI: 10.1146/annurev.bi.56.070187.000513. (Classic paper on metabolic channeling, including the TCA cycle "metabolon" concept.)
- Michael S. Brown and Joseph L. Goldstein, 'A Receptor-Mediated Pathway for Cholesterol Homeostasis,' Science, vol. 232, no. 4746, 1986, pp. 34–47. DOI: 10.1126/science.3513311. (Nobel Prize lecture describing the SREBP/SCAP/INSIG system regulating HMG-CoA reductase and cholesterol homeostasis.)